Functional	O
correction	O
of	O
FA-C	B-cell_type
cells	I-cell_type
with	O
FANCC	B-protein
suppresses	O
the	O
expression	O
of	O
interferon	B-DNA
gamma-inducible	I-DNA
genes	I-DNA
.	O

Because	O
hematopoietic	B-cell_type
cells	I-cell_type
derived	O
from	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
patients	O
of	O
the	O
C-complementation	O
group	O
(	O
FA-C	O
)	O
are	O
hypersensitive	O
to	O
the	O
inhibitory	O
effects	O
of	O
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
,	O
the	O
products	O
of	O
certain	O
IFNgamma-inducible	B-DNA
genes	I-DNA
known	O
to	O
influence	O
hematopoietic	O
cell	O
survival	O
were	O
quantified	O
.	O

High	O
constitutive	O
expression	O
of	O
the	O
IFNgamma-inducible	B-DNA
genes	I-DNA
,	O
IFN-stimulated	B-protein
gene	I-protein
factor	I-protein
3	I-protein
gamma	I-protein
subunit	I-protein
(	O
ISGF3gamma	B-protein
)	O
,	O
IFN	B-protein
regulatory	I-protein
factor-1	I-protein
(	O
IRF-1	B-protein
)	O
,	O
and	O
the	O
cyclin-dependent	B-protein
kinase	I-protein
inhibitor	I-protein
p21	I-protein
(	O
WAF1	B-protein
)	O
was	O
found	O
in	O
FANCC	B-protein
mutant	O
B	B-cell_type
lymphoblasts	I-cell_type
,	O
low-density	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
and	O
murine	B-cell_type
embryonic	I-cell_type
fibroblasts	I-cell_type
.	O

Paradoxically	O
,	O
these	O
cells	O
do	O
not	O
activate	B-protein
signal	I-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
1	I-protein
properly	O
.	O

In	O
an	O
attempt	O
to	O
clarify	O
mechanisms	O
by	O
which	O
FA-C	B-cell_type
cells	I-cell_type
overexpress	O
IFNgamma-inducible	B-DNA
genes	I-DNA
in	O
the	O
face	O
of	O
defective	O
STAT1	O
phosphorylation	O
,	O
it	O
was	O
reasoned	O
that	O
decreased	O
levels	O
of	O
activated	B-protein
STAT1	I-protein
might	O
result	O
in	O
reduced	O
expression	O
of	O
a	O
hematopoietic	B-protein
IFNgamma-responsive	I-protein
protein	I-protein
that	O
normally	O
modulates	O
expression	O
of	O
other	O
IFNgamma-responsive	B-DNA
genes	I-DNA
.	O

Levels	O
of	O
the	O
IFNgamma	B-protein
-inducible	O
factor	O
IFN	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
(	O
ICSBP	B-protein
)	O
,	O
a	O
negative	B-protein
trans-acting	I-protein
regulator	I-protein
of	O
some	O
IFNgamma-inducible	B-DNA
genes	I-DNA
,	O
were	O
quantified	O
.	O

ICSBP	B-protein
levels	O
were	O
reduced	O
in	O
FA-C	B-cell_type
B	I-cell_type
lymphoblasts	I-cell_type
and	O
MEFs	B-cell_type
.	O

However	O
,	O
enforced	O
expression	O
of	O
ICSBP	B-protein
failed	O
to	O
down-regulate	O
IRF-1	B-protein
,	O
ISGF3gamma	B-protein
,	O
and	O
p21	B-protein
(	I-protein
WAF1	I-protein
)	I-protein
.	O

Thus	O
,	O
the	O
FANCC	B-protein
protein	I-protein
functions	O
to	O
modulate	O
expression	O
of	O
a	O
family	O
of	O
genes	O
that	O
in	O
normal	O
cells	O
are	O
inducible	O
only	O
by	O
specific	O
environmental	O
cues	O
for	O
apoptosis	O
or	O
mitogenic	O
inhibition	O
,	O
but	O
it	O
does	O
so	O
independently	O
of	O
the	O
classic	O
IFN-STAT1	O
pathway	O
and	O
is	O
not	O
the	O
direct	O
result	O
of	O
reduced	O
ICSBP	B-protein
expression	O
.	O

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

HEMATOPOIESIS	NULL
Functional	NULL
correction	NULL
of	NULL
FA-C	NULL
cells	NULL
with	NULL
FANCC	NULL
suppresses	NULL
the	NULL
expression	NULL
of	NULL
interferon	NULL
y-inducible	NULL
genes	NULL
Sara	NULL
R.	NULL
Fagerlie	NULL
,	NULL
Jane	NULL
Diaz	NULL
,	NULL
Tracy	NULL
A.	NULL
Christianson	NULL
,	NULL
Kelli	NULL
McCartan	NULL
,	NULL
Winifred	NULL
Keeble	NULL
,	NULL
Gregory	NULL
R.	NULL
Faulkner	NULL
,	NULL
and	NULL
Grover	NULL
C.	NULL
Bagby	NULL
Because	NULL
hematopoietic	NULL
cells	NULL
derived	NULL
from	NULL
Fanconi	NULL
anemia	NULL
(	NULL
FA	NULL
)	NULL
patients	NULL
of	NULL
the	NULL
C-complementation	NULL
group	NULL
(	NULL
FA-C	NULL
)	NULL
are	NULL
hypersensitive	NULL
to	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
interferon	NULL
y	NULL
(	NULL
IFNy	NULL
)	NULL
,	NULL
the	NULL
products	NULL
of	NULL
certain	NULL
IFNy-inducible	NULL
genes	NULL
known	NULL
to	NULL
influence	NULL
hematopoietic	NULL
cell	NULL
survival	NULL
were	NULL
quantified	NULL
.	NULL

High	NULL
constitutive	NULL
expression	NULL
of	NULL
the	NULL
IFNy-inducible	NULL
genes	NULL
,	NULL
IFN-stimulated	NULL
gene	NULL
factor	NULL
3	NULL
gamma	NULL
subunit	NULL
(	NULL
ISGF3y	NULL
)	NULL
,	NULL
IFN	NULL
regulatory	NULL
factor-1	NULL
(	NULL
IRF-1	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
p21W4	NULL
``	NULL
!	NULL

was	NULL
found	NULL
in	NULL
FANCC	NULL
mutant	NULL
B	NULL
lymphoblasts	NULL
,	NULL
low-density	NULL
bone	NULL
marrow	NULL
cells	NULL
,	NULL
doxically	NULL
,	NULL
these	NULL
cells	NULL
do	NULL
not	NULL
activate	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
1	NULL
properly	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
clarify	NULL
mechanisms	NULL
by	NULL
which	NULL
FA-C	NULL
cells	NULL
overexpress	NULL
IFNy-inducible	NULL
genes	NULL
in	NULL
the	NULL
face	NULL
of	NULL
defective	NULL
STAT1	NULL
phosphorylation	NULL
,	NULL
it	NULL
was	NULL
reasoned	NULL
that	NULL
decreased	NULL
levels	NULL
of	NULL
activated	NULL
STAT1	NULL
might	NULL
result	NULL
in	NULL
reduced	NULL
expression	NULL
of	NULL
a	NULL
hematopoietic	NULL
IFNy-responsive	NULL
protein	NULL
that	NULL
normally	NULL
modulates	NULL
expression	NULL
of	NULL
other	NULL
IFNy-responsive	NULL
genes	NULL
.	NULL

Levels	NULL
of	NULL
the	NULL
IFNy-inducible	NULL
factor	NULL
IFN	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
(	NULL
ICSBP	NULL
)	NULL
,	NULL
a	NULL
negative	NULL
trans-acting	NULL
regulator	NULL
of	NULL
some	NULL
IFNy-inducible	NULL
genes	NULL
,	NULL
were	NULL
quantified	NULL
.	NULL

ICSBP	NULL
levels	NULL
were	NULL
reduced	NULL
in	NULL
FA-C	NULL
B	NULL
lymphoblasts	NULL
and	NULL
MEFs	NULL
.	NULL

However	NULL
,	NULL
enforced	NULL
expression	NULL
of	NULL
ICSBP	NULL
failed	NULL
to	NULL
down-regulate	NULL
IRF-1	NULL
,	NULL
ISGF3y	NULL
,	NULL
and	NULL
p21W	NULL
``	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
FANCC	NULL
protein	NULL
functions	NULL
to	NULL
modulate	NULL
expression	NULL
of	NULL
a	NULL
family	NULL
of	NULL
genes	NULL
that	NULL
in	NULL
normal	NULL
cells	NULL
are	NULL
inducible	NULL
only	NULL
by	NULL
specific	NULL
environmental	NULL
cues	NULL
for	NULL
apoptosis	NULL
or	NULL
mitogenic	NULL
inhibi-tion	NULL
,	NULL
but	NULL
it	NULL
does	NULL
so	NULL
independently	NULL
of	NULL
the	NULL
classic	NULL
IFN-STAT1	NULL
pathway	NULL
and	NULL
is	NULL
not	NULL
the	NULL
direct	NULL
result	NULL
of	NULL
reduced	NULL
ICSBP	NULL
expression	NULL
.	NULL

(	NULL
Blood	NULL
.	NULL

2001	NULL
;	NULL
97:3017-3024	NULL
)	NULL
and	NULL
murine	NULL
embryonic	NULL
fibroblasts	NULL
.	NULL

Para-	NULL
Introduction	NULL
Â©2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
Fanconi	NULL
anemia	NULL
(	NULL
FA	NULL
)	NULL
is	NULL
an	NULL
autosomal	NULL
recessive	NULL
disease	NULL
characterized	NULL
by	NULL
progressive	NULL
bone	NULL
marrow	NULL
failure	NULL
,	NULL
multiple	NULL
congenital	NULL
anomalies	NULL
,	NULL
and	NULL
a	NULL
high	NULL
incidence	NULL
of	NULL
acute	NULL
myelogenous	NULL
leukemia	NULL
.	NULL
``	NULL

Cells	NULL
from	NULL
FA	NULL
patients	NULL
are	NULL
hypersensitive	NULL
to	NULL
the	NULL
effects	NULL
of	NULL
DNA	NULL
cross-linking	NULL
agents	NULL
,	NULL
such	NULL
as	NULL
mitomycin	NULL
C	NULL
and	NULL
diepoxybutane	NULL
.	NULL
``	NULL

The	NULL
disorder	NULL
is	NULL
genetically	NULL
heterogeneous	NULL
,	NULL
with	NULL
at	NULL
least	NULL
7	NULL
different	NULL
complementation	NULL
groups	NULL
.	NULL
``	NULL

The	NULL
genes	NULL
corresponding	NULL
to	NULL
group	NULL
A	NULL
(	NULL
FANCA	NULL
)	NULL
,	NULL
C	NULL
(	NULL
FANCC	NULL
)	NULL
,	NULL
E	NULL
(	NULL
FANCE	NULL
)	NULL
,	NULL
F	NULL
(	NULL
FANCF	NULL
)	NULL
,	NULL
and	NULL
G	NULL
(	NULL
FANCG	NULL
)	NULL
have	NULL
been	NULL
cloned	NULL
.	NULL
``	NULL

''	NULL
``	NULL
Fanconi	NULL
gene	NULL
sequences	NULL
show	NULL
no	NULL
significant	NULL
homology	NULL
to	NULL
any	NULL
known	NULL
genes	NULL
,	NULL
and	NULL
the	NULL
functions	NULL
of	NULL
their	NULL
gene	NULL
products	NULL
are	NULL
Hematopoietic	NULL
precursor	NULL
cells	NULL
from	NULL
children	NULL
with	NULL
FA	NULL
of	NULL
the	NULL
C	NULL
complementation	NULL
group	NULL
(	NULL
FA-C	NULL
)	NULL
are	NULL
excessively	NULL
apoptotic	NULL
and	NULL
hypersensitive	NULL
to	NULL
a	NULL
variety	NULL
of	NULL
cytokines	NULL
known	NULL
to	NULL
induce	NULL
apoptosis	NULL
,	NULL
including	NULL
interferon	NULL
y	NULL
(	NULL
IFNy	NULL
)	NULL
.	NULL

IFNy	NULL
is	NULL
a	NULL
cytokine	NULL
involved	NULL
in	NULL
host	NULL
defense	NULL
against	NULL
viral	NULL
infections	NULL
and	NULL
regulation	NULL
of	NULL
cell	NULL
growth	NULL
.	NULL

!	NULL
``	NULL

IFNy	NULL
clearly	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
hematopoietic	NULL
suppression	NULL
and	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
acquired	NULL
aplastic	NULL
ane-mia	NULL
.	NULL
``	NULL

Cells	NULL
with	NULL
inactivating	NULL
FANCC	NULL
mutations	NULL
are	NULL
hypersensitive	NULL
to	NULL
the	NULL
apoptotic	NULL
effects	NULL
of	NULL
IFNy	NULL
,	NULL
an	NULL
effect	NULL
that	NULL
depends	NULL
in	NULL
part	NULL
on	NULL
an	NULL
intact	NULL
fas/fas-ligand	NULL
pathway	NULL
.	NULL
``	NULL

Specifically	NULL
,	NULL
exposure	NULL
to	NULL
low	NULL
doses	NULL
of	NULL
IFNy	NULL
in	NULL
vitro	NULL
primes	NULL
a	NULL
substantial	NULL
fraction	NULL
of	NULL
FA-C	NULL
progenitor	NULL
cells	NULL
to	NULL
undergo	NULL
apoptosis	NULL
after	NULL
subsequent	NULL
exposure	NULL
to	NULL
fas	NULL
ligand	NULL
.	NULL

Such	NULL
doses	NULL
of	NULL
IFNy	NULL
have	NULL
no	NULL
effect	NULL
on	NULL
normal	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
.	NULL

``	NULL
>	NULL
>	NULL
Because	NULL
of	NULL
the	NULL
influence	NULL
of	NULL
IFNy	NULL
on	NULL
the	NULL
fas	NULL
pathway	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
other	NULL
IFNy-inducible	NULL
genes	NULL
are	NULL
hyperactive	NULL
in	NULL
FA-C	NULL
cells	NULL
.	NULL

We	NULL
carried	NULL
out	NULL
studies	NULL
designed	NULL
to	NULL
analyze	NULL
expression	NULL
of	NULL
IFNy-inducible	NULL
genes	NULL
known	NULL
to	NULL
promote	NULL
apoptosis	NULL
and/or	NULL
mitogenic	NULL
inhibition	NULL
in	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
.	NULL

We	NULL
describe	NULL
here	NULL
studies	NULL
revealing	NULL
that	NULL
the	NULL
transactivators	NULL
interferon	NULL
regulatory	NULL
factor-1	NULL
(	NULL
IRF-1	NULL
)	NULL
and	NULL
IFN-stimulated	NULL
gene	NULL
factor	NULL
3	NULL
gamma	NULL
subunit	NULL
(	NULL
ISGF3y	NULL
)	NULL
and	NULL
the	NULL
cyclin-dependent	NULL
kinase	NULL
(	NULL
cdk	NULL
)	NULL
inhibitor	NULL
p21	NULL
WA*	NULL
``	NULL
are	NULL
expressed	NULL
at	NULL
constitutively	NULL
higher	NULL
levels	NULL
in	NULL
FA-C	NULL
B	NULL
lymphoblasts	NULL
,	NULL
low-density	NULL
bone	NULL
marrow	NULL
cells	NULL
(	NULL
LDBMCs	NULL
)	NULL
,	NULL
and	NULL
murine	NULL
embryonic	NULL
fibroblasts	NULL
(	NULL
MEFs	NULL
)	NULL
,	NULL
compared	NULL
with	NULL
cells	NULL
expressing	NULL
a	NULL
normal	NULL
FANCC	NULL
.	NULL

However	NULL
,	NULL
these	NULL
proteins	NULL
are	NULL
expressed	NULL
at	NULL
normal	NULL
levels	NULL
in	NULL
mature	NULL
mutant	NULL
fibro-blasts	NULL
,	NULL
suggesting	NULL
some	NULL
degree	NULL
of	NULL
tissue	NULL
or	NULL
developmental	NULL
stage	NULL
specificity	NULL
of	NULL
FANCC	NULL
function	NULL
in	NULL
control	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

IFNy	NULL
exerts	NULL
its	NULL
effects	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
through	NULL
the	NULL
Jak/signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
signaling	NULL
path-way	NULL
,	NULL
``	NULL
``	NULL
``	NULL
``	NULL
However	NULL
,	NULL
FA-C	NULL
cells	NULL
are	NULL
defective	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
properly	NULL
activate	NULL
STAT1	NULL
.	NULL

``	NULL
Â°	NULL
We	NULL
show	NULL
here	NULL
that	NULL
up-regulation	NULL
of	NULL
IFNy-inducible	NULL
genes	NULL
occurs	NULL
precisely	NULL
in	NULL
those	NULL
cell	NULL
types	NULL
that	NULL
fail	NULL
to	NULL
properly	NULL
activate	NULL
STAT1	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
loss	NULL
of	NULL
a	NULL
STAT1-inducible	NULL
transcriptional	NULL
repressor	NULL
may	NULL
result	NULL
in	NULL
up-regulation	NULL
of	NULL
IFNy-inducible	NULL
genes	NULL
in	NULL
FA-C	NULL
cells	NULL
.	NULL

Indeed	NULL
,	NULL
we	NULL
found	NULL
expression	NULL
of	NULL
the	NULL
transcriptional	NULL
repressor	NULL
IFN	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
(	NULL
ICSBP	NULL
)	NULL
is	NULL
decreased	NULL
in	NULL
both	NULL
FA-C	NULL
B	NULL
lymphoblasts	NULL
and	NULL
murine	NULL
embryonic	NULL
fibroblasts	NULL
.	NULL

However	NULL
,	NULL
enforced	NULL
expression	NULL
of	NULL
ICSBP	NULL
failed	NULL
to	NULL
suppress	NULL
IRF-1	NULL
,	NULL
ISGF37y	NULL
,	NULL
or	NULL
p21	NULL
WAFL	NULL
,	NULL
From	NULL
the	NULL
Division	NULL
of	NULL
Hematology	NULL
and	NULL
Medical	NULL
Oncology	NULL
,	NULL
the	NULL
Department	NULL
of	NULL
Molecular	NULL
and	NULL
Medical	NULL
Genetics	NULL
,	NULL
and	NULL
the	NULL
Oregon	NULL
Cancer	NULL
Center	NULL
,	NULL
Oregon	NULL
Health	NULL
Sciences	NULL
University	NULL
;	NULL
and	NULL
the	NULL
Molecular	NULL
Hematopoiesis	NULL
Laboratory	NULL
,	NULL
VA	NULL
Medical	NULL
Center	NULL
,	NULL
Portland	NULL
,	NULL
OR	NULL
.	NULL

Submitted	NULL
January	NULL
1	NULL
,	NULL
1999	NULL
;	NULL
accepted	NULL
January	NULL
9	NULL
,	NULL
2001	NULL
.	NULL

Supported	NULL
by	NULL
grant	NULL
HL48546	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

BLOOD	NULL
,	NULL
15	NULL
MAY	NULL
2001	NULL
Â«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
10	NULL
Reprints	NULL
:	NULL
Grover	NULL
C.	NULL
Bagby	NULL
,	NULL
Oregon	NULL
Cancer	NULL
Center	NULL
,	NULL
Oregon	NULL
Health	NULL
Sciences	NULL
University	NULL
,	NULL
CR-145	NULL
,	NULL
3181	NULL
SW	NULL
Sam	NULL
Jackson	NULL
Park	NULL
Rd	NULL
,	NULL
Portland	NULL
,	NULL
OR	NULL
97201	NULL
;	NULL
e-mail	NULL
:	NULL
grover	NULL
@	NULL
ohsu.edu	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

Therefore	NULL
,	NULL
and	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
,	NULL
this	NULL
article	NULL
is	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
.	NULL

Â©2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
3017	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3018	NULL
_	NULL
FAGERLIE	NULL
etal	NULL
We	NULL
conclude	NULL
that	NULL
in	NULL
FA-C	NULL
hematopoietic	NULL
and	NULL
embryonic	NULL
cells	NULL
,	NULL
expression	NULL
of	NULL
IFNy-inducible	NULL
genes	NULL
is	NULL
increased	NULL
even	NULL
in	NULL
the	NULL
face	NULL
of	NULL
defective	NULL
STAT1	NULL
phosphorylation	NULL
but	NULL
is	NULL
not	NULL
linked	NULL
directly	NULL
with	NULL
reduced	NULL
levels	NULL
of	NULL
ICSBP	NULL
.	NULL

We	NULL
suggest	NULL
that	NULL
FANCC	NULL
functions	NULL
to	NULL
indirectly	NULL
suppress	NULL
expression	NULL
of	NULL
IFNy-inducible	NULL
genes	NULL
in	NULL
a	NULL
cell-type-specific	NULL
,	NULL
STAT	NULL
1-independent	NULL
manner	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cell	NULL
culture	NULL
and	NULL
IFNy	NULL
stimulation	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-transformed	NULL
human	NULL
lymphoblasts	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
media	NULL
1640	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
supplemented	NULL
with	NULL
15	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
grown	NULL
in	NULL
a	NULL
humidified	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
p-containing	NULL
atmosphere	NULL
at	NULL
37Â°C	NULL
.	NULL

The	NULL
FA-A	NULL
B-lymphoblast	NULL
lines	NULL
HSC72	NULL
and	NULL
HSC72/FANCC	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr	NULL
Walsh	NULL
(	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
,	NULL
Chapel	NULL
Hill	NULL
)	NULL
.	NULL

The	NULL
lymphoblast	NULL
lines	NULL
JY	NULL
(	NULL
normal	NULL
)	NULL
,	NULL
HSC536N	NULL
(	NULL
FANCC	NULL
mutant	NULL
)	NULL
,	NULL
HSC536N/FANCC	NULL
,	NULL
and	NULL
HSC536N/neo	NULL
were	NULL
described	NULL
previously	NULL
.	NULL

Briefly	NULL
,	NULL
HSC536N/FANCC	NULL
was	NULL
derived	NULL
by	NULL
transducing	NULL
the	NULL
HSC536N	NULL
with	NULL
a	NULL
retrovirus	NULL
encoding	NULL
both	NULL
FANCC	NULL
and	NULL
neomycin	NULL
phosphotransferase	NULL
(	NULL
neo	NULL
)	NULL
.	NULL

The	NULL
HSC536N/neo	NULL
line	NULL
was	NULL
derived	NULL
by	NULL
transducing	NULL
the	NULL
HSC536N	NULL
with	NULL
a	NULL
vector	NULL
encoding	NULL
for	NULL
neomycin	NULL
phosphotransferase	NULL
alone	NULL
.	NULL

MEFs	NULL
were	NULL
established	NULL
from	NULL
FancC	NULL
knockout	NULL
and	NULL
wild-type	NULL
mice	NULL
as	NULL
previously	NULL
described	NULL
``	NULL
and	NULL
grown	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

MEFs	NULL
were	NULL
transformed	NULL
and	NULL
immortalized	NULL
by	NULL
SV40	NULL
large	NULL
T	NULL
antigen	NULL
.	NULL
``	NULL

The	NULL
following	NULL
Fanconi	NULL
fibroblast	NULL
lines	NULL
were	NULL
received	NULL
from	NULL
the	NULL
Oregon	NULL
Health	NULL
Sciences	NULL
University	NULL
Fanconi	NULL
Anemia	NULL
Cell	NULL
Repository	NULL
:	NULL
PD134	NULL
(	NULL
FA-C	NULL
)	NULL
;	NULL
PD426/FANCA	NULL
(	NULL
FA-C-expressing	NULL
FANCA	NULL
)	NULL
;	NULL
PD426/FANCC	NULL
(	NULL
FA-C	NULL
corrected	NULL
)	NULL
;	NULL
PD331.T	NULL
(	NULL
FA-C	NULL
)	NULL
;	NULL
PD720/FANCC	NULL
(	NULL
FA-A-expressing	NULL
FANCC	NULL
)	NULL
;	NULL
PD720/FANCA	NULL
(	NULL
FA-A	NULL
corrected	NULL
)	NULL
;	NULL
ML7334	NULL
(	NULL
FA-G	NULL
)	NULL
;	NULL
and	NULL
ML7334/FANCG	NULL
(	NULL
FA-G	NULL
corrected	NULL
)	NULL
.	NULL

Human	NULL
primary	NULL
fibroblasts	NULL
cell	NULL
lines	NULL
were	NULL
established	NULL
by	NULL
means	NULL
of	NULL
standard	NULL
procedures	NULL
.	NULL
``	NULL

''	NULL
The	NULL
PD331.T	NULL
line	NULL
was	NULL
immortalized	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

'	NULL
Cells	NULL
were	NULL
grown	NULL
in	NULL
MEM-	NULL
Â«	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
supplemented	NULL
with	NULL
20	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

Correction	NULL
of	NULL
PD134	NULL
and	NULL
PD331	NULL
was	NULL
done	NULL
by	NULL
means	NULL
of	NULL
a	NULL
retroviral	NULL
vector	NULL
carrying	NULL
the	NULL
human	NULL
FANCC	NULL
complementary	NULL
DNA	NULL
(	NULL
cDNA	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Cells	NULL
were	NULL
incubated	NULL
with	NULL
virus	NULL
for	NULL
3	NULL
hours	NULL
twice	NULL
daily	NULL
over	NULL
a	NULL
5-day	NULL
period	NULL
and	NULL
then	NULL
selected	NULL
with	NULL
G418	NULL
.	NULL

ICSBP-expressing	NULL
HSC536N	NULL
cells	NULL
were	NULL
made	NULL
by	NULL
means	NULL
of	NULL
a	NULL
PLXSN-based	NULL
retroviral	NULL
vector	NULL
expressing	NULL
the	NULL
human	NULL
ICSBP	NULL
cDNA	NULL
.	NULL

The	NULL
pLXSN	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr	NULL
A.	NULL
D.	NULL
Miller	NULL
(	NULL
Fred	NULL
Hutchinson	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
.	NULL

The	NULL
pTarget/ICSBP	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
supplied	NULL
by	NULL
Dr	NULL
Ben-Zion	NULL
Levi	NULL
(	NULL
Technion-Israel	NULL
Institute	NULL
of	NULL
Technology	NULL
,	NULL
Haifa	NULL
,	NULL
Israel	NULL
)	NULL
and	NULL
contains	NULL
the	NULL
entire	NULL
human	NULL
ICSBP	NULL
cDNA	NULL
.	NULL

The	NULL
pLXSN/ICSBP	NULL
was	NULL
made	NULL
as	NULL
follows	NULL
:	NULL
pTarget/ICSBP	NULL
was	NULL
digested	NULL
with	NULL
EcoRI	NULL
;	NULL
a	NULL
1.3-kilobase	NULL
insert	NULL
was	NULL
isolated	NULL
and	NULL
cloned	NULL
into	NULL
pLXSN	NULL
.	NULL

Proper	NULL
orientation	NULL
was	NULL
determined	NULL
by	NULL
means	NULL
of	NULL
a	NULL
Kpnl/NotI	NULL
digest	NULL
.	NULL

Viruses	NULL
were	NULL
made	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

HSC536N	NULL
were	NULL
incubated	NULL
with	NULL
pLXSN/ICSBP	NULL
or	NULL
pLXSN	NULL
virus	NULL
plus	NULL
8	NULL
g/mL	NULL
polybrene	NULL
for	NULL
3	NULL
hours	NULL
twice	NULL
daily	NULL
for	NULL
5	NULL
days	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
selected	NULL
with	NULL
G418	NULL
.	NULL

IFNy	NULL
treatment	NULL
MEFs	NULL
were	NULL
serum	NULL
starved	NULL
for	NULL
24	NULL
hours	NULL
and	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
amount	NULL
of	NULL
recombinant	NULL
murine	NULL
IFNy	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
at	NULL
at	NULL
37Â°C	NULL
.	NULL

B	NULL
lymphoblasts	NULL
and	NULL
human	NULL
primary	NULL
fibroblasts	NULL
were	NULL
treated	NULL
with	NULL
the	NULL
indicated	NULL
amounts	NULL
of	NULL
recombinant	NULL
human	NULL
IFNy	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
at	NULL
37Â°C	NULL
.	NULL

Preparation	NULL
of	NULL
total	NULL
cell	NULL
lysates	NULL
and	NULL
nuclear	NULL
extracts	NULL
Total	NULL
cell	NULL
lysates	NULL
were	NULL
made	NULL
by	NULL
washing	NULL
cells	NULL
twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
and	NULL
cell	NULL
pellets	NULL
were	NULL
solubilized	NULL
in	NULL
RIPA	NULL
:	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
BLOOD	NULL
,	NULL
15	NULL
MAY	NULL
2001	NULL
Â«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
10	NULL
(	NULL
SDS	NULL
)	NULL
,	NULL
1	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
aprotinin	NULL
,	NULL
2	NULL
mM	NULL
Na	NULL
;	NULL
VO,4	NULL
,	NULL
1	NULL
g/mL	NULL
leupeptin	NULL
,	NULL
1	NULL
g/mL	NULL
pepstatin	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
phenylmethylsulfonylfluoride	NULL
(	NULL
PMSF	NULL
)	NULL
.	NULL

Lysates	NULL
were	NULL
centrifuged	NULL
at	NULL
16	NULL
000g	NULL
for	NULL
15	NULL
minutes	NULL
at	NULL
4Â°C	NULL
,	NULL
and	NULL
protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
means	NULL
of	NULL
protein	NULL
micro-assay	NULL
of	NULL
the	NULL
Bradford	NULL
method	NULL
(	NULL
BioRad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
ice-cold	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
cold	NULL
hypotonic	NULL
buffer	NULL
:	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
1.5	NULL
mM	NULL
MgC12	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
]	NULL
,	NULL
0.2	NULL
mM	NULL
PMSF	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
2	NULL
pg/mL	NULL
aprotinin	NULL
,	NULL
and	NULL
2	NULL
g/mL	NULL
leupeptin	NULL
.	NULL

Cells	NULL
were	NULL
allowed	NULL
to	NULL
swell	NULL
on	NULL
ice	NULL
10	NULL
minutes	NULL
and	NULL
then	NULL
lysed	NULL
with	NULL
a	NULL
Dounce	NULL
B	NULL
homogenizer	NULL
(	NULL
Bellco	NULL
Glass	NULL
,	NULL
Vineland	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Nuclei	NULL
were	NULL
pelleted	NULL
at	NULL
3300g	NULL
for	NULL
20	NULL
minutes	NULL
at	NULL
4Â°C	NULL
and	NULL
then	NULL
resuspended	NULL
in	NULL
low-salt	NULL
buffer	NULL
:	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
1.5	NULL
mM	NULL
MgC12	NULL
,	NULL
20	NULL
mM	NULL
KC1	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.2	NULL
mM	NULL
PMSF	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
2	NULL
pg/mL	NULL
aprotinin	NULL
,	NULL
and	NULL
2	NULL
g/mL	NULL
leupeptin	NULL
.	NULL

High-salt	NULL
buffer	NULL
(	NULL
0.6	NULL
M	NULL
KCI	NULL
)	NULL
was	NULL
added	NULL
dropwise	NULL
,	NULL
and	NULL
nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
by	NULL
incubation	NULL
at	NULL
4Â°C	NULL
for	NULL
30	NULL
minutes	NULL
and	NULL
centrifuged	NULL
at	NULL
13	NULL
000g	NULL
for	NULL
30	NULL
minutes	NULL
at	NULL
4Â°C	NULL
.	NULL

Supernatants	NULL
were	NULL
dialyzed	NULL
at	NULL
4Â°C	NULL
for	NULL
3	NULL
to	NULL
5	NULL
hours	NULL
against	NULL
a	NULL
250-fold	NULL
volume	NULL
excess	NULL
of	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH7.9	NULL
,	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
100	NULL
mM	NULL
KCI	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.2	NULL
mM	NULL
PMSF	NULL
,	NULL
0.5	NULL
raM	NULL
DTT	NULL
,	NULL
2.g/mL	NULL
aprotinin	NULL
,	NULL
and	NULL
2	NULL
pg/mL	NULL
leupeptin	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
Total	NULL
cell	NULL
lysates	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
mixed	NULL
with	NULL
Laemmli	NULL
sample	NULL
buffer	NULL
,	NULL
``	NULL
heated	NULL
at	NULL
94Â°C	NULL
for	NULL
5	NULL
minutes	NULL
.	NULL

Equivalent	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
subjected	NULL
to	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
electroblotted	NULL
onto	NULL
Bio-Blot	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Blots	NULL
were	NULL
then	NULL
subjected	NULL
to	NULL
Ponceau	NULL
S.	NULL
staining	NULL
to	NULL
demonstrate	NULL
equivalent	NULL
loading	NULL
.	NULL

Nonspecific	NULL
binding	NULL
was	NULL
blocked	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
plus	NULL
0.05	NULL
%	NULL
Tween	NULL
20	NULL
(	NULL
TBS-T	NULL
)	NULL
containing	NULL
5	NULL
%	NULL
milk	NULL
.	NULL

Blots	NULL
were	NULL
incubated	NULL
with	NULL
primary	NULL
antibody	NULL
,	NULL
washed	NULL
with	NULL
TBS-T	NULL
,	NULL
then	NULL
incubated	NULL
with	NULL
secondary	NULL
antibody	NULL
,	NULL
and	NULL
washed	NULL
again	NULL
with	NULL
TBS-T.	NULL
Antibody-reactive	NULL
proteins	NULL
were	NULL
detected	NULL
by	NULL
means	NULL
of	NULL
Enhanced	NULL
Chemilu-minescence	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

IRF-1	NULL
antibody	NULL
(	NULL
1:1000	NULL
)	NULL
,	NULL
p21	NULL
``	NULL
*	NULL
``	NULL
``	NULL
antibody	NULL
(	NULL
1:500	NULL
)	NULL
,	NULL
ISGF3y	NULL
(	NULL
BD	NULL
Pharmingen	NULL
)	NULL
(	NULL
1:250	NULL
)	NULL
,	NULL
p27	NULL
``	NULL
(	NULL
BD	NULL
Pharmingen	NULL
)	NULL
(	NULL
1:500	NULL
)	NULL
,	NULL
p53	NULL
(	NULL
1:1000	NULL
)	NULL
,	NULL
IRF-2	NULL
(	NULL
1:1000	NULL
)	NULL
,	NULL
and	NULL
total	NULL
STAT1	NULL
(	NULL
1:2000	NULL
)	NULL
were	NULL
used	NULL
at	NULL
the	NULL
indicated	NULL
dilutions	NULL
and	NULL
incubated	NULL
with	NULL
the	NULL
blots	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Donkey	NULL
antirabbit	NULL
immunoglobulin	NULL
G	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
HRP	NULL
)	NULL
secondary	NULL
antibody	NULL
(	NULL
1:5000	NULL
)	NULL
(	NULL
Amersham	NULL
)	NULL
was	NULL
used	NULL
against	NULL
these	NULL
primary	NULL
antibodies	NULL
.	NULL

ICSBP	NULL
antibody	NULL
was	NULL
diluted	NULL
1:500	NULL
for	NULL
1	NULL
hour	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Rabbit	NULL
antigoat	NULL
HRP	NULL
secondary	NULL
antibody	NULL
(	NULL
1:2000	NULL
)	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
was	NULL
used	NULL
against	NULL
ICSBP	NULL
primary	NULL
antibody	NULL
.	NULL

Phospho-specific	NULL
STAT1	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
(	NULL
1:500	NULL
)	NULL
was	NULL
incubated	NULL
at	NULL
4Â°C	NULL
overnight	NULL
.	NULL

Donkey	NULL
antirabbit	NULL
HRP	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
(	NULL
1:2000	NULL
)	NULL
secondary	NULL
antibody	NULL
was	NULL
used	NULL
against	NULL
phosphorylated	NULL
STAT1	NULL
primary	NULL
antibody	NULL
.	NULL

Antibodies	NULL
were	NULL
used	NULL
at	NULL
the	NULL
indicated	NULL
dilutions	NULL
and	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
CA	NULL
)	NULL
unless	NULL
otherwise	NULL
indicated	NULL
.	NULL

Electromobility	NULL
shift	NULL
assay	NULL
Sequences	NULL
for	NULL
oligonucleotides	NULL
used	NULL
in	NULL
binding	NULL
reactions	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
human	NULL
IRF-1	NULL
gamma	NULL
activation	NULL
sequence	NULL
(	NULL
GAS	NULL
)	NULL
,	NULL
5-ACAACAGCCTGATT-TCCCCGAA-3	NULL
``	NULL
;	NULL
murine	NULL
IRF-1	NULL
GAS	NULL
,	NULL
5	NULL
``	NULL
-CCTGATTITTCCCCGAAATGATG-3	NULL
'	NULL
;	NULL
murine	NULL
ICSBP	NULL
GAS	NULL
,	NULL
5	NULL
``	NULL
-AGTGATTTCTCGGAAAGAGAG-3	NULL
'	NULL
.	NULL

Oligonucleotides	NULL
were	NULL
synthesized	NULL
at	NULL
the	NULL
Molecular	NULL
Biology	NULL
Core	NULL
Laboratory	NULL
(	NULL
Portland	NULL
,	NULL
OR	NULL
,	NULL
Veterans	NULL
Affairs	NULL
Medical	NULL
Center	NULL
)	NULL
,	NULL
then	NULL
labeled	NULL
with	NULL
[	NULL
y*P-ATP	NULL
]	NULL
to	NULL
25	NULL
000	NULL
cpm/ng	NULL
by	NULL
means	NULL
of	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
Roche	NULL
Molecular	NULL
Biochemical	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
(	NULL
20	NULL
L	NULL
)	NULL
contained	NULL
5.0	NULL
to	NULL
7.5	NULL
ug	NULL
nuclear	NULL
extracts	NULL
,	NULL
0.2	NULL
ng	NULL
labeled	NULL
oligo	NULL
,	NULL
2	NULL
pg	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
and	NULL
10	NULL
g	NULL
bovine	NULL
serum	NULL
albumin	NULL
in	NULL
10	NULL
mM	NULL
Tris-Cl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
50	NULL
rmiM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
10	NULL
%	NULL
glycerol	NULL
.	NULL

Reactions	NULL
were	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
minutes	NULL
and	NULL
then	NULL
resolved	NULL
on	NULL
a	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
25	NULL
mM	NULL
Tris	NULL
,	NULL
190	NULL
mM	NULL
glycine	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
autoradiographed	NULL
with	NULL
intensifying	NULL
screens	NULL
at	NULL
-80Â°C	NULL
.	NULL

RNA	NULL
isolation	NULL
,	NULL
cDNA	NULL
synthesis	NULL
,	NULL
and	NULL
real-time	NULL
reverse-transcriptase	NULL
polymerase	NULL
chain	NULL
reaction	NULL
Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
cells	NULL
with	NULL
TriReagent	NULL
(	NULL
Molecular	NULL
Research	NULL
Center	NULL
,	NULL
Cincinnati	NULL
,	NULL
OH	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

We	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
15	NULL
MAY	NULL
2001	NULL
Â«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
10	NULL
performed	NULL
cDNA	NULL
synthesis	NULL
with	NULL
1	NULL
jug	NULL
total	NULL
RNA	NULL
,	NULL
200	NULL
ng	NULL
random	NULL
hexamers	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
,	NULL
and	NULL
Superscript	NULL
II	NULL
reverse	NULL
transcriptase	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
cDNAs	NULL
were	NULL
then	NULL
diluted	NULL
to	NULL
an	NULL
approximate	NULL
concentration	NULL
of	NULL
20	NULL
ng/mL	NULL
before	NULL
performing	NULL
the	NULL
amplification	NULL
reactions	NULL
.	NULL

Amplifications	NULL
were	NULL
performed	NULL
in	NULL
an	NULL
ABI	NULL
Prism	NULL
7700	NULL
Sequence	NULL
Detection	NULL
System	NULL
(	NULL
PE	NULL
Applied	NULL
Biosystems	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
by	NULL
means	NULL
of	NULL
100	NULL
ng	NULL
cDNA	NULL
,	NULL
7.5	NULL
pmol	NULL
each	NULL
target	NULL
primer	NULL
,	NULL
2.5	NULL
pmol	NULL
target	NULL
probe	NULL
,	NULL
2.5	NULL
pmol	NULL
each	NULL
housekeeping	NULL
primer	NULL
,	NULL
and	NULL
2.5	NULL
pmol	NULL
housekeeping	NULL
probe	NULL
(	NULL
h18S	NULL
)	NULL
.	NULL

As	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
,	NULL
the	NULL
TagMan	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
kit	NULL
(	NULL
PE	NULL
Applied	NULL
Biosystems	NULL
)	NULL
was	NULL
used	NULL
as	NULL
directed	NULL
.	NULL

The	NULL
primer	NULL
and	NULL
probe	NULL
sequences	NULL
,	NULL
designed	NULL
by	NULL
means	NULL
of	NULL
ABI	NULL
Primer	NULL
Express	NULL
software	NULL
(	NULL
PE	NULL
Applied	NULL
Biosystems	NULL
)	NULL
and	NULL
synthesized	NULL
by	NULL
Integrated	NULL
DNA	NULL
Technologies	NULL
(	NULL
Coralville	NULL
,	NULL
IA	NULL
)	NULL
,	NULL
are	NULL
as	NULL
follows	NULL
:	NULL
hMxA	NULL
(	NULL
forward	NULL
primer	NULL
)	NULL
5	NULL
``	NULL
-TGGTGGTGGTCCCCAGTAAT-3	NULL
'	NULL
;	NULL
hMxA	NULL
(	NULL
reverse	NULL
A	NULL
``	NULL
T	NULL
U	NULL
~d	NULL
y	NULL
0	NULL
E-	NULL
J	NULL
<	NULL
9	NULL
Q	NULL
2	NULL
Â§	NULL
ts	NULL
5	NULL
2	NULL
-B	NULL
.	NULL

-	NULL
ZZZ	NULL
i	NULL
w	NULL
ww	NULL
Z	NULL
=s	NULL
-	NULL
AGb	NULL
2	NULL
9	NULL
EL	NULL
H	NULL
J	NULL
UVU	NULL
post	NULL
.	NULL

{	NULL
H	NULL
~	NULL
a	NULL
a	NULL
A	NULL
A	NULL
a	NULL
%	NULL
&	NULL
&	NULL
Â«	NULL
*=	NULL
wc	NULL
``	NULL
mf	NULL
a	NULL
--	NULL
IRF-1	NULL
cae	NULL
~	NULL
ants	NULL
-	NULL
taas	NULL
*-	NULL
ISGF3y	NULL
r	NULL
.	NULL

***	NULL
--	NULL
B-tubulin	NULL
as	NULL
like	NULL
s	NULL
MKA	NULL
szlWAFi	NULL
me	NULL
WBR	NULL
-	NULL
p27	NULL
``	NULL
102	NULL
3	NULL
40	NULL
S	NULL
6	NULL
7	NULL
8	NULL
B	NULL
H	NULL
y	NULL
MxA	NULL
E	NULL
T	NULL
5	NULL
a	NULL
E	NULL
P	NULL
3	NULL
1	NULL
*s	NULL
HSC536N	NULL
HSC536N	NULL
HSCS36N	NULL
/FANCC	NULL
__	NULL
/nco	NULL
C	NULL
-	NULL
<	NULL
D	NULL
CJ	NULL
4	NULL
L	NULL
S	NULL
g	NULL
px	NULL
~	NULL
a	NULL
E.	NULL
a	NULL
.	NULL

S	NULL
5	NULL
2	NULL
8	NULL
&	NULL
Â£	NULL
cÂ£	NULL
.	NULL

IRF-1	NULL
Feats	NULL
-IRF-1	NULL
w	NULL
Â®	NULL
+-1SGF3Yy	NULL
~-	NULL
ISGF3y	NULL
mee	NULL
|	NULL
.-	NULL
p21	NULL
``	NULL
'	NULL
ma	NULL
ty	NULL
--	NULL
pS53	NULL
Poo	NULL
:	NULL
3	NULL
hulk	NULL
2	NULL
_	NULL
pzlwmfl	NULL
wee	NULL
.	NULL

-	NULL
[	NULL
-tubulin	NULL
ee	NULL
FANCC	NULL
SUPPRESSES	NULL
IFNy-INDUCIBLE	NULL
GENE	NULL
EXPRESSION	NULL
_	NULL
3019	NULL
primer	NULL
)	NULL
5-CGTCAAGATTCCGATGGTCC-3	NULL
'	NULL
;	NULL
hMxA	NULL
(	NULL
dual	NULL
labeled	NULL
probe	NULL
)	NULL
5'-FAM-CCACCACAGAGGCTCTCAGCATGG-TAMRA-3	NULL
'	NULL
;	NULL
h188	NULL
(	NULL
for	NULL
ward	NULL
primer	NULL
)	NULL
5'-CGGCTACCACATCCAAGGAA-3	NULL
'	NULL
;	NULL
h188	NULL
(	NULL
reverse	NULL
primer	NULL
)	NULL
5-GGGCCTCGA	NULL
AAGAGTCCTGT-3	NULL
'	NULL
;	NULL
and	NULL
188	NULL
Probe	NULL
5'-VIC-CA	NULL
GCAGGCGCGCAAATTACCCA-TAMRA-3	NULL
'	NULL
.	NULL

Results	NULL
Constitutive	NULL
overexpression	NULL
of	NULL
IFNy-inducible	NULL
genes	NULL
in	NULL
mutant	NULL
FA-C	NULL
cell	NULL
lines	NULL
Because	NULL
FA-C	NULL
cells	NULL
are	NULL
hypersensitive	NULL
to	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
IFNy	NULL
,	NULL
``	NULL
we	NULL
quantified	NULL
protein	NULL
levels	NULL
of	NULL
transcriptional	NULL
activators	NULL
known	NULL
to	NULL
be	NULL
downstream	NULL
of	NULL
the	NULL
IFNy/Jak/STAT	NULL
pathway	NULL
by	NULL
immunoblot	NULL
analysis	NULL
of	NULL
total	NULL
cell	NULL
lysates	NULL
or	NULL
nuclear	NULL
extracts	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
IFNy-inducible	NULL
transactivating	NULL
factors	NULL
IRF-1	NULL
and	NULL
ISGF37y	NULL
consistently	NULL
revealed	NULL
high	NULL
constitutive	NULL
expression	NULL
levels	NULL
in	NULL
nuclear	NULL
extracts	NULL
and	NULL
whole	NULL
cell	NULL
lysates	NULL
derived	NULL
from	NULL
the	NULL
FancC	NULL
mutant	NULL
MEF	NULL
cell	NULL
line	NULL
(	NULL
MEF61	NULL
)	NULL
compared	NULL
with	NULL
the	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
MEF	NULL
cell	NULL
line	NULL
(	NULL
MEF11.1	NULL
)	NULL
.	NULL

We	NULL
observed	NULL
the	NULL
same	NULL
phenomenon	NULL
using	NULL
(	NULL
1	NULL
)	NULL
whole	NULL
cell	NULL
lysates	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
EBV-transformed	NULL
FANCC	NULL
mutant	NULL
human	NULL
B-lymphoblast	NULL
line	NULL
HSC536N	NULL
;	NULL
(	NULL
2	NULL
)	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
EBV-transformed	NULL
B-lymphoblast	NULL
line	NULL
PD149	NULL
,	NULL
relative	NULL
to	NULL
levels	NULL
in	NULL
those	NULL
cells	NULL
corrected	NULL
for	NULL
the	NULL
defect	NULL
by	NULL
retroviral	NULL
transduction	NULL
of	NULL
the	NULL
normal	NULL
FANCC	NULL
cDNA	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
;	NULL
and	NULL
(	NULL
3	NULL
)	NULL
whole	NULL
cell	NULL
lysates	NULL
from	NULL
LDBMCs	NULL
derived	NULL
from	NULL
FA	NULL
patients	NULL
compared	NULL
with	NULL
LDBMCs	NULL
derived	NULL
from	NULL
a	NULL
normal	NULL
person	NULL
(	NULL
Figure	NULL
1D	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
have	NULL
previously	NULL
found	NULL
constitutively	NULL
high	NULL
expression	NULL
of	NULL
IRF-1	NULL
messenger	NULL
RNA	NULL
(	NULL
mRNA	NULL
)	NULL
also	NULL
occurs	NULL
in	NULL
diploid	NULL
bone	NULL
marrow	NULL
cells	NULL
from	NULL
children	NULL
with	NULL
FA-C	NULL
but	NULL
not	NULL
in	NULL
normal	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
no	NULL
differences	NULL
in	NULL
IRF-2	NULL
expression	NULL
levels	NULL
were	NULL
found	NULL
between	NULL
FA-C	NULL
cells	NULL
and	NULL
normal	NULL
cells	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
mRNA	NULL
levels	NULL
of	NULL
the	NULL
IFNy-inducible	NULL
guanosine	NULL
triphosphatase	NULL
(	NULL
GTPase	NULL
)	NULL
MxA	NULL
are	NULL
reduced	NULL
in	NULL
the	NULL
HSC536N	NULL
B-lymphoblast	NULL
line	NULL
compared	NULL
with	NULL
corrected	NULL
cells	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

We	NULL
found	NULL
no	NULL
differences	NULL
in	NULL
IRF-1	NULL
and	NULL
ISGF3y	NULL
expression	NULL
in	NULL
the	NULL
FA-A	NULL
lymphoblast	NULL
line	NULL
HSC72	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
.	NULL

We	NULL
next	NULL
quantified	NULL
levels	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
modulator	NULL
p21	NULL
WA	NULL
``	NULL
``	NULL
,	NULL
which	NULL
is	NULL
known	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
IRF-1	NULL
and	NULL
FA-C	NULL
B	NULL
lymphoblasts	NULL
,	NULL
MEFs	NULL
,	NULL
and	NULL
LDBMC	NULL
's	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
p21	NULL
WA*	NULL
``	NULL
!	NULL

compared	NULL
with	NULL
normal	NULL
or	NULL
corrected	NULL
cells	NULL
(	NULL
Figure	NULL
1A	NULL
,	NULL
D	NULL
)	NULL
.	NULL

The	NULL
FA-A	NULL
cell	NULL
line	NULL
HSC:72	NULL
also	NULL
expresses	NULL
higher	NULL
levels	NULL
of	NULL
p21W	NULL
``	NULL
``	NULL
compared	NULL
with	NULL
corrected	NULL
cells	NULL
,	NULL
but	NULL
does	NULL
not	NULL
overexpress	NULL
IRF-1	NULL
or	NULL
ISGF3y	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
overexpression	NULL
of	NULL
the	NULL
transactivators	NULL
IRF-1	NULL
and	NULL
ISGF3y	NULL
and	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
inhibitor	NULL
p21	NULL
YA	NULL
``	NULL
may	NULL
Figure	NULL
1	NULL
.	NULL

Expression	NULL
of	NULL
IRF-1	NULL
,	NULL
ISGF3y	NULL
,	NULL
and	NULL
p21	NULL
``	NULL
*	NULL
``	NULL
``	NULL
is	NULL
reduced	NULL
in	NULL
FA-C	NULL
MEFs	NULL
,	NULL
B	NULL
lymphoblasts	NULL
,	NULL
and	NULL
FA	NULL
patient	NULL
LDBMCs	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Immunoblot	NULL
analysis	NULL
of	NULL
the	NULL
FancC	NULL
mutant	NULL
MEF	NULL
cell	NULL
line	NULL
(	NULL
MEF61	NULL
)	NULL
shows	NULL
increased	NULL
expression	NULL
levels	NULL
of	NULL
IRF-1	NULL
,	NULL
ISGF3g	NULL
,	NULL
and	NULL
compared	NULL
with	NULL
the	NULL
WT	NULL
MEF	NULL
cell	NULL
line	NULL
(	NULL
MEF1.1	NULL
)	NULL
(	NULL
lane	NULL
2	NULL
vs	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
FANCC	NULL
mutant	NULL
B-lymphoblast	NULL
line	NULL
HSC536N	NULL
,	NULL
the	NULL
HSC536N	NULL
line	NULL
transduced	NULL
with	NULL
a	NULL
vector	NULL
only	NULL
(	NULL
HSC536N/neo	NULL
)	NULL
,	NULL
and	NULL
PD149	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
,	NULL
respectively	NULL
)	NULL
show	NULL
increased	NULL
IRF-1	NULL
,	NULL
and	NULL
expression	NULL
compared	NULL
with	NULL
the	NULL
normal	NULL
cell	NULL
line	NULL
JY	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
with	NULL
cells	NULL
corrected	NULL
for	NULL
the	NULL
defect	NULL
by	NULL
retroviral	NULL
transduction	NULL
of	NULL
the	NULL
FANCC	NULL
cDNA	NULL
(	NULL
HSC536N/FANCC	NULL
)	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
or	NULL
PD149/FANCC	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

However	NULL
,	NULL
FA-C	NULL
cells	NULL
express	NULL
normal	NULL
levels	NULL
of	NULL
IRF-2	NULL
,	NULL
p53	NULL
,	NULL
and	NULL
To	NULL
demonstrate	NULL
equivalent	NULL
loading	NULL
of	NULL
the	NULL
ISGF3y	NULL
blots	NULL
,	NULL
B-tubulin	NULL
is	NULL
used	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Real-time	NULL
reverse	NULL
transcriptase	NULL
PCR	NULL
demonstrates	NULL
up-regulation	NULL
of	NULL
MxA	NULL
in	NULL
HSCS36N	NULL
and	NULL
HSC536N/	NULL
neo	NULL
compared	NULL
with	NULL
the	NULL
corrected	NULL
cells	NULL
HSC53GN/FANCC	NULL
.	NULL

This	NULL
is	NULL
a	NULL
representative	NULL
experiment	NULL
.	NULL

Error	NULL
bars	NULL
are	NULL
based	NULL
on	NULL
duplicate	NULL
samples	NULL
.	NULL

(	NULL
C	NULL
)	NULL
The	NULL
FA-C	NULL
cell	NULL
line	NULL
HSC72	NULL
expresses	NULL
equivalent	NULL
levels	NULL
of	NULL
IRF-1	NULL
and	NULL
ISGF3y	NULL
compared	NULL
with	NULL
cells	NULL
corrected	NULL
for	NULL
the	NULL
defect	NULL
.	NULL

The	NULL
cells	NULL
do	NULL
express	NULL
slightly	NULL
more	NULL
p21WA	NULL
``	NULL
'	NULL
,	NULL
but	NULL
equivalent	NULL
p53	NULL
.	NULL

To	NULL
demonstrate	NULL
equivalent	NULL
loading	NULL
of	NULL
the	NULL
p21	NULL
blot	NULL
,	NULL
B-tubulin	NULL
is	NULL
used	NULL
.	NULL

(	NULL
D	NULL
)	NULL
LDBMCs	NULL
derived	NULL
from	NULL
2	NULL
FA	NULL
patients	NULL
show	NULL
up-regulation	NULL
of	NULL
IRF-1	NULL
,	NULL
ISGF3y	NULL
,	NULL
and	NULL
p21WA	NULL
``	NULL
compared	NULL
with	NULL
cells	NULL
derived	NULL
from	NULL
normal	NULL
individual	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
vs	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3020	NULL
-	NULL
FAGERLIE	NULL
etal	NULL
be	NULL
due	NULL
to	NULL
abnormalities	NULL
in	NULL
different	NULL
pathways	NULL
,	NULL
one	NULL
of	NULL
which	NULL
is	NULL
influenced	NULL
by	NULL
both	NULL
FANCA	NULL
and	NULL
FANCC	NULL
and	NULL
the	NULL
other	NULL
by	NULL
FANCC	NULL
alone	NULL
.	NULL

We	NULL
found	NULL
no	NULL
differences	NULL
in	NULL
p53	NULL
binding	NULL
to	NULL
its	NULL
p21	NULL
binding	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
minimal	NULL
differences	NULL
in	NULL
p53	NULL
expression	NULL
levels	NULL
,	NULL
indicating	NULL
that	NULL
p21W	NULL
``	NULL
``	NULL
overexpression	NULL
is	NULL
p53-independent	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

No	NULL
differences	NULL
in	NULL
expression	NULL
levels	NULL
of	NULL
the	NULL
cdk	NULL
inhibitor	NULL
p27	NULL
``	NULL
were	NULL
found	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

We	NULL
found	NULL
no	NULL
differences	NULL
in	NULL
protein	NULL
levels	NULL
of	NULL
IRF-1	NULL
,	NULL
ISGF3Yy	NULL
,	NULL
and	NULL
p21W	NULL
``	NULL
``	NULL
in	NULL
mature	NULL
primary	NULL
human	NULL
FA	NULL
fibroblasts	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

Finding	NULL
molecular	NULL
differences	NULL
between	NULL
mature	NULL
fibroblasts	NULL
and	NULL
hematopoietic	NULL
cells	NULL
is	NULL
not	NULL
surprising	NULL
given	NULL
that	NULL
hematopoietic	NULL
abnormalities	NULL
represent	NULL
the	NULL
dominant	NULL
phenotype	NULL
in	NULL
FA	NULL
patients	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
finding	NULL
that	NULL
a	NULL
normal	NULL
FANCC	NULL
is	NULL
required	NULL
for	NULL
proper	NULL
regulation	NULL
of	NULL
IRF-1	NULL
,	NULL
p21W*	NULL
``	NULL
``	NULL
,	NULL
and	NULL
ISGF3y	NULL
in	NULL
hematopoietic	NULL
cells	NULL
and	NULL
embryonic	NULL
fibroblasts	NULL
but	NULL
not	NULL
in	NULL
mature	NULL
fibroblasts	NULL
suggests	NULL
that	NULL
MEFs	NULL
have	NULL
retained	NULL
more	NULL
plasticity	NULL
and	NULL
may	NULL
exhibit	NULL
responses	NULL
more	NULL
reflective	NULL
of	NULL
hematopoietic	NULL
and	NULL
germ	NULL
cells	NULL
than	NULL
adult	NULL
fibroblasts	NULL
.	NULL

FA-C	NULL
cells	NULL
overexpressing	NULL
IFNy-inducible	NULL
genes	NULL
are	NULL
deficient	NULL
in	NULL
STAT1	NULL
phosphorylation	NULL
FA-C	NULL
cells	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
defective	NULL
in	NULL
STAT	NULL
1	NULL
phosphorylation	NULL
,	NULL
despite	NULL
having	NULL
normal	NULL
activation	NULL
of	NULL
the	NULL
IFNy	NULL
receptor	NULL
,	NULL
JAK	NULL
1	NULL
,	NULL
and	NULL
JAK2	NULL
.	NULL

``	NULL
Â°	NULL
We	NULL
sought	NULL
to	NULL
determine	NULL
if	NULL
this	NULL
occurred	NULL
in	NULL
cells	NULL
that	NULL
overexpress	NULL
IFNy-inducible	NULL
genes	NULL
and	NULL
those	NULL
that	NULL
do	NULL
not	NULL
.	NULL

We	NULL
analyzed	NULL
the	NULL
levels	NULL
of	NULL
phosphorylated	NULL
STAT1	NULL
in	NULL
IFNy-induced	NULL
cells	NULL
.	NULL

MEFs	NULL
were	NULL
serum	NULL
starved	NULL
for	NULL
24	NULL
hours	NULL
and	NULL
then	NULL
incubated	NULL
at	NULL
37Â°C	NULL
with	NULL
1	NULL
ng/mL	NULL
of	NULL
murine	NULL
IFNy	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
periods	NULL
.	NULL

Using	NULL
immunoblot	NULL
analysis	NULL
,	NULL
we	NULL
determined	NULL
that	NULL
in	NULL
both	NULL
total	NULL
cell	NULL
lysates	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
MEFs	NULL
,	NULL
the	NULL
level	NULL
of	NULL
phosphorylated	NULL
STAT1	NULL
was	NULL
significantly	NULL
decreased	NULL
in	NULL
FancC	NULL
mutant	NULL
cells	NULL
compared	NULL
with	NULL
the	NULL
WT	NULL
cells	NULL
.	NULL

When	NULL
these	NULL
blots	NULL
were	NULL
stripped	NULL
and	NULL
reprobed	NULL
for	NULL
total	NULL
STAT1	NULL
,	NULL
levels	NULL
of	NULL
total	NULL
STAT1	NULL
were	NULL
equivalent	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
analysis	NULL
of	NULL
total	NULL
cell	NULL
lysates	NULL
from	NULL
the	NULL
mutant	NULL
FANCC	NULL
B-cell	NULL
lines	NULL
HSC536N	NULL
and	NULL
HSC536N/neo	NULL
demonstrated	NULL
that	NULL
the	NULL
amount	NULL
of	NULL
phosphorylated	NULL
STAT1	NULL
was	NULL
diminished	NULL
when	NULL
compared	NULL
with	NULL
the	NULL
normal	NULL
cell	NULL
line	NULL
JY	NULL
and	NULL
the	NULL
FANCC-transduced	NULL
cell	NULL
line	NULL
HSC536N/FANCC	NULL
.	NULL

When	NULL
the	NULL
same	NULL
blots	NULL
were	NULL
stripped	NULL
and	NULL
reprobed	NULL
for	NULL
STAT1	NULL
,	NULL
total	NULL
STATl	NULL
was	NULL
slightly	NULL
increased	NULL
in	NULL
the	NULL
mutant	NULL
cells	NULL
(	NULL
but	NULL
phosphorylated	NULL
levels	NULL
were	NULL
ae	NULL
@	NULL
U	NULL
<	NULL
-	NULL
U	NULL
C	NULL
UQ	NULL
U	NULL
UV	NULL
24	NULL
s	NULL
VQ	NULL
V	NULL
Z	NULL
,	NULL
2	NULL
s	NULL
2	NULL
Z	NULL
4	NULL
P	NULL
2	NULL
%	NULL
Z	NULL
<	NULL
4	NULL
4	NULL
a	NULL
<	NULL
<	NULL
S	NULL
2	NULL
<	NULL
4	NULL
<	NULL
H=	NULL
=	NULL
2	NULL
6	NULL
&	NULL
=-	NULL
Fh	NULL
E	NULL
E	NULL
``	NULL
%	NULL
to	NULL
dod	NULL
Â©	NULL
8	NULL
-	NULL
-	NULL
-	NULL
S	NULL
S	NULL
#	NULL
im	NULL
oj	NULL
ge	NULL
a	NULL
mo	NULL
om	NULL
a	NULL
-	NULL
~-	NULL
O	NULL
to-aBad	NULL
A	NULL
A	NULL
B	NULL
A	NULL
B	NULL
aA	NULL
g	NULL
g	NULL
&	NULL
A	NULL
&	NULL
A	NULL
Â£	NULL
A	NULL
&	NULL
A	NULL
A	NULL
A	NULL
A	NULL
A	NULL
a	NULL
a	NULL
w	NULL
-	NULL
Â«	NULL
o	NULL
Â«	NULL
--	NULL
-	NULL
CGD	NULL
CID	NULL
@	NULL
ame	NULL
am	NULL
e	NULL
om	NULL
~	NULL
S	NULL
C83	NULL
)	NULL
CGE	NULL
~	NULL
.	NULL

_-	NULL
ame	NULL
ame	NULL
cmmg	NULL
E	NULL
MAK	NULL
a	NULL
i	NULL
-IRF-1	NULL
wite	NULL
cm	NULL
dlls	NULL
sae	NULL
cm	NULL
|	NULL
wms	NULL
.	NULL

quais	NULL
dh	NULL
ï¬	NULL
'	NULL
n	NULL
v__p2|wy\r|_-p1	NULL
?	NULL

.-1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
60	NULL
70	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
Figure	NULL
2	NULL
.	NULL

Human	NULL
FA	NULL
fibroblasts	NULL
express	NULL
equivalent	NULL
levels	NULL
of	NULL
IRF-1	NULL
,	NULL
ISGF3y	NULL
,	NULL
and	NULL
p21	NULL
``	NULL
4	NULL
``	NULL
``	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
of	NULL
human	NULL
FA-C	NULL
fibroblasts	NULL
PD134	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
PD134/neo	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
PD426/FANCA	NULL
(	NULL
lane5	NULL
)	NULL
,	NULL
PD331.T	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
and	NULL
PD331.T/neo	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
;	NULL
the	NULL
FA-A	NULL
fibroblasts	NULL
PD720/FANCC	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
;	NULL
and	NULL
the	NULL
FA-G	NULL
fibroblast	NULL
line	NULL
ML7334	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
express	NULL
equivalent	NULL
levels	NULL
of	NULL
ISGF3y	NULL
,	NULL
IRF-1	NULL
,	NULL
and	NULL
p21W**	NULL
'	NULL
compared	NULL
with	NULL
those	NULL
cells	NULL
corrected	NULL
for	NULL
the	NULL
defect	NULL
by	NULL
retroviral	NULL
transduction	NULL
of	NULL
the	NULL
appropriate	NULL
FA	NULL
cDNA	NULL
:	NULL
PD134/FANCC	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
PD426/FANCC	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
PD331.T/FANCC	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
PD720/	NULL
FANCA	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
,	NULL
ML7334/FANCG	NULL
(	NULL
lane	NULL
12	NULL
)	NULL
.	NULL

BLOOD	NULL
,	NULL
15	NULL
MAY	NULL
2001	NULL
Â«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
10	NULL
A	NULL
-_	NULL
MEFIL1	NULL
(	NULL
WT	NULL
)	NULL
_	NULL
MEF6I	NULL
(	NULL
FaneC/	NULL
)	NULL
[	NULL
o	NULL
so	NULL
so	NULL
1201	NULL
]	NULL
o	NULL
30Â°	NULL
so	NULL
'	NULL
120Â°	NULL
|	NULL
irny	NULL
we	NULL
cme	NULL
--	NULL
-	NULL
__Nuclear	NULL
P-	NULL
Stat	NULL
1	NULL
Â«	NULL
ene	NULL
come	NULL
_	NULL
Total	NULL
P-	NULL
Stat	NULL
1	NULL
``	NULL
ap	NULL
m=	NULL
emy	NULL
qui	NULL
wore	NULL
nene	NULL
Â»	NULL
aaa	NULL
-	NULL
Total	NULL
Stat	NULL
1	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
B	NULL
JY	NULL
HSCS36N	NULL
HSCS36N	NULL
HSCS36N	NULL
/FANCC	NULL
__/neo	NULL
[	NULL
o	NULL
15	NULL
]	NULL
0	NULL
0	NULL
s	NULL
'	NULL
]	NULL
0	NULL
15	NULL
]	NULL
em	NULL
?	NULL

Â»	NULL
__	NULL
-e	NULL
-	NULL
eum	NULL
_	NULL
Â«	NULL
**	NULL
s	NULL
i	NULL
i	NULL
a	NULL
us	NULL
i	NULL
Wk	NULL
S..	NULL
i	NULL
;	NULL
1	NULL
2	NULL
3	NULL
-	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
Figure	NULL
3	NULL
.	NULL

STAT1i	NULL
phosphorylation	NULL
at	NULL
tyrosine	NULL
701	NULL
is	NULL
reduced	NULL
in	NULL
MEFs	NULL
and	NULL
B	NULL
lymphoblasts	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Immunoblot	NULL
analysis	NULL
demonstrates	NULL
that	NULL
phosphorylation	NULL
of	NULL
STAT1	NULL
is	NULL
reduced	NULL
in	NULL
both	NULL
nuclear	NULL
extracts	NULL
and	NULL
total	NULL
cell	NULL
extracts	NULL
(	NULL
upper	NULL
and	NULL
middle	NULL
panel	NULL
respectively	NULL
)	NULL
from	NULL
FancC/~	NULL
MEFs	NULL
(	NULL
MEF61	NULL
)	NULL
(	NULL
lanes	NULL
5	NULL
through	NULL
8	NULL
)	NULL
compared	NULL
with	NULL
WT	NULL
cells	NULL
(	NULL
MEF11.1	NULL
)	NULL
(	NULL
anes	NULL
1	NULL
though	NULL
4	NULL
)	NULL
following	NULL
stimulation	NULL
with	NULL
1	NULL
ng/mL	NULL
IFNy	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

Total	NULL
STAT1	NULL
levels	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
were	NULL
equivalent	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
4	NULL
compared	NULL
with	NULL
lanes	NULL
5	NULL
through	NULL
8	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Phosphorylation	NULL
of	NULL
STATA	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
is	NULL
reduced	NULL
in	NULL
total	NULL
cell	NULL
extracts	NULL
from	NULL
HSC536N	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
and	NULL
HSCS536N/neo	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
compared	NULL
with	NULL
JY	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
and	NULL
HSC536N/FANCC	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
following	NULL
stimulation	NULL
with	NULL
1	NULL
ng/mL	NULL
IFNy	NULL
at	NULL
37Â°C	NULL
for	NULL
15	NULL
minutes	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Total	NULL
STAT1	NULL
levels	NULL
were	NULL
slightly	NULL
higher	NULL
in	NULL
the	NULL
mutant	NULL
cells	NULL
(	NULL
but	NULL
phosphorylation	NULL
levels	NULL
are	NULL
reduced	NULL
)	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

decreased	NULL
)	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
STAT1	NULL
phosphorylation	NULL
was	NULL
found	NULL
to	NULL
be	NULL
normal	NULL
in	NULL
all	NULL
mature	NULL
human	NULL
FA	NULL
fibroblast	NULL
lines	NULL
tested	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
FA	NULL
cells	NULL
,	NULL
STAT1	NULL
phosphorylation	NULL
defects	NULL
are	NULL
specific	NULL
to	NULL
certain	NULL
cell	NULL
types	NULL
,	NULL
and	NULL
paradoxically	NULL
,	NULL
those	NULL
cell	NULL
types	NULL
defective	NULL
in	NULL
STAT1	NULL
activation	NULL
have	NULL
high	NULL
constitutive	NULL
expression	NULL
of	NULL
several	NULL
IFNy-inducible	NULL
genes	NULL
.	NULL

Reduced	NULL
binding	NULL
to	NULL
the	NULL
GAS	NULL
element	NULL
in	NULL
FA-C	NULL
cells	NULL
It	NULL
was	NULL
theoretically	NULL
possible	NULL
that	NULL
a	NULL
more	NULL
complete	NULL
and	NULL
rapid	NULL
nuclear	NULL
translocation	NULL
of	NULL
STAT1	NULL
in	NULL
FA-C	NULL
cells	NULL
might	NULL
have	NULL
given	NULL
an	NULL
appearance	NULL
of	NULL
reduced	NULL
STAT1	NULL
activation	NULL
.	NULL

Consequently	NULL
,	NULL
we	NULL
asked	NULL
whether	NULL
apparently	NULL
reduced	NULL
levels	NULL
of	NULL
STAT	NULL
1	NULL
phosphorylation	NULL
were	NULL
associated	NULL
with	NULL
increased	NULL
binding	NULL
to	NULL
the	NULL
STAT1	NULL
response	NULL
element	NULL
,	NULL
GAS	NULL
.	NULL

Using	NULL
an	NULL
oligonucleotide	NULL
derived	NULL
from	NULL
the	NULL
GAS	NULL
element	NULL
of	NULL
murine	NULL
IRF-1	NULL
for	NULL
electromobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
analysis	NULL
of	NULL
murine	NULL
MEF	NULL
lines	NULL
,	NULL
we	NULL
found	NULL
that	NULL
IFNy-inducible	NULL
binding	NULL
to	NULL
the	NULL
GAS	NULL
element	NULL
was	NULL
significantly	NULL
reduced	NULL
in	NULL
the	NULL
FancC-~-	NULL
MEF	NULL
line	NULL
compared	NULL
with	NULL
the	NULL
WT	NULL
MEF	NULL
line	NULL
(	NULL
Figure	NULL
5A	NULL
)	NULL
.	NULL

Using	NULL
oligonucleotides	NULL
representing	NULL
the	NULL
human	NULL
IRF-1	NULL
GAS	NULL
element	NULL
,	NULL
we	NULL
found	NULL
that	NULL
;	NULL
Â¢	NULL
Pa	NULL
J	NULL
o	NULL
e	NULL
Â¢	NULL
S	NULL
9	NULL
9	NULL
y	NULL
t	NULL
P	NULL
Z	NULL
e	NULL
Z	NULL
,	NULL
Z	NULL
,	NULL
&	NULL
E	NULL
<	NULL
B	NULL
<	NULL
<	NULL
s	NULL
&	NULL
-	NULL
&	NULL
&	NULL
l	NULL
E	NULL
E	NULL
A	NULL
hs	NULL
&	NULL
&	NULL
&	NULL
=	NULL
=	NULL
a	NULL
a	NULL
35	NULL
a	NULL
&	NULL
&	NULL
A	NULL
8	NULL
A	NULL
&	NULL
&	NULL
.	NULL

&	NULL
&	NULL
&	NULL
&	NULL
Â£	NULL
.	NULL

&	NULL
.	NULL

+	NULL
-	NULL
+	NULL
*	NULL
f	NULL
-	NULL
%	NULL
=	NULL
(	NULL
B	NULL
&	NULL
i	NULL
%	NULL
-	NULL
+	NULL
)	NULL
IFNy	NULL
Â«	NULL
se	NULL
wae	NULL
.	NULL

caP	NULL
Â«	NULL
ae	NULL
wae	NULL
@	NULL
@	NULL
_	NULL
eme	NULL
_	NULL
gee	NULL
wee	NULL
wit	NULL
won	NULL
pas	NULL
pos	NULL
com	NULL
.	NULL

Gol	NULL
wee	NULL
woe	NULL
gees	NULL
.	NULL

one	NULL
umm	NULL
*	NULL
I	NULL
2	NULL
304	NULL
5	NULL
6	NULL
T	NULL
%	NULL
9	NULL
10	NULL
I1	NULL
42	NULL
d3	NULL
140	NULL
15	NULL
16	NULL
Figure	NULL
4	NULL
.	NULL

Normal	NULL
phosphorylation	NULL
of	NULL
STAT1i	NULL
in	NULL
mature	NULL
FA-C	NULL
fibroblasts	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
of	NULL
human	NULL
FA-C	NULL
fibroblasts	NULL
by	NULL
means	NULL
of	NULL
an	NULL
antibody	NULL
specific	NULL
for	NULL
phosphorylated	NULL
STAT1	NULL
demonstrates	NULL
that	NULL
STAT1	NULL
is	NULL
phosphorylated	NULL
equivalently	NULL
between	NULL
mutant	NULL
and	NULL
corrected	NULL
IFNy-stimulated	NULL
cells	NULL
(	NULL
1	NULL
ng/mL	NULL
IFNy	NULL
)	NULL
(	NULL
top	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
total	NULL
STATA	NULL
is	NULL
expressed	NULL
at	NULL
approximately	NULL
equal	NULL
levels	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
15	NULL
MAY	NULL
2001	NULL
Â«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
10	NULL
IFNy-inducible	NULL
binding	NULL
was	NULL
not	NULL
detectable	NULL
in	NULL
mutant	NULL
FANCC	NULL
human	NULL
B	NULL
cells	NULL
,	NULL
whereas	NULL
normal	NULL
inducible	NULL
binding	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
FANCC-complemented	NULL
cell	NULL
line	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
diminished	NULL
ability	NULL
to	NULL
phosphorylate	NULL
STAT1	NULL
in	NULL
FA-C	NULL
cells	NULL
results	NULL
in	NULL
decreased	NULL
activated	NULL
STAT1	NULL
nuclear	NULL
translocation	NULL
and	NULL
binding	NULL
to	NULL
GAS	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
IFNy	NULL
response	NULL
modulator	NULL
ICSBP	NULL
is	NULL
reduced	NULL
in	NULL
the	NULL
FA-C	NULL
cell	NULL
lines	NULL
Seeking	NULL
to	NULL
identify	NULL
potential	NULL
molecular	NULL
points	NULL
of	NULL
control	NULL
involved	NULL
in	NULL
the	NULL
aberrant	NULL
expression	NULL
of	NULL
IRF-1	NULL
,	NULL
and	NULL
ISGF3y	NULL
in	NULL
FA-C	NULL
cells	NULL
,	NULL
we	NULL
quantified	NULL
ICSBP	NULL
,	NULL
an	NULL
interferon-responsive	NULL
transcription	NULL
factor	NULL
known	NULL
to	NULL
modulate	NULL
IFN	NULL
responses	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

``	NULL
``	NULL
``	NULL
>	NULL
ICSBP	NULL
levels	NULL
were	NULL
constitutively	NULL
low	NULL
in	NULL
HSC536N	NULL
and	NULL
HSC536N/	NULL
neo	NULL
cell	NULL
lines	NULL
compared	NULL
with	NULL
the	NULL
normal	NULL
cell	NULL
line	NULL
JY	NULL
and	NULL
the	NULL
complemented	NULL
line	NULL
HSC536N/FANCC	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
although	NULL
ICSBP	NULL
is	NULL
reported	NULL
to	NULL
be	NULL
expressed	NULL
mainly	NULL
in	NULL
hematopoietic	NULL
cells	NULL
,	NULL
we	NULL
found	NULL
ICSBP	NULL
expression	NULL
to	NULL
be	NULL
consistently	NULL
inducible	NULL
in	NULL
WT	NULL
MEFs	NULL
as	NULL
well	NULL
.	NULL

Expression	NULL
of	NULL
ICSBP	NULL
is	NULL
significantly	NULL
decreased	NULL
in	NULL
FANCC	NULL
mutant	NULL
MEFs	NULL
.	NULL

Therefore	NULL
a	NULL
functional	NULL
FANCC	NULL
is	NULL
necessary	NULL
for	NULL
optimal	NULL
constitutive	NULL
expression	NULL
of	NULL
ICSBP	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
find	NULL
reduced	NULL
binding	NULL
to	NULL
the	NULL
GAS	NULL
element	NULL
derived	NULL
from	NULL
murine	NULL
ICSBP	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
decreased	NULL
ICSBP	NULL
expression	NULL
may	NULL
be	NULL
a	NULL
direct	NULL
result	NULL
of	NULL
reduced	NULL
STAT	NULL
1	NULL
phosphorylation	NULL
.	NULL

Enforced	NULL
expression	NULL
of	NULL
ICSBP	NULL
does	NULL
not	NULL
suppress	NULL
IRF-1	NULL
,	NULL
p21WAFV/CP1	NULL
,	NULL
or	NULL
|SGF37y	NULL
To	NULL
examine	NULL
the	NULL
linkage	NULL
of	NULL
reduced	NULL
ICSBP	NULL
with	NULL
overexpression	NULL
of	NULL
IRF-1	NULL
,	NULL
ISGF3y	NULL
,	NULL
or	NULL
p21W	NULL
``	NULL
``	NULL
,	NULL
we	NULL
transduced	NULL
the	NULL
HSC536N	NULL
B-lymphoblast	NULL
cell	NULL
line	NULL
with	NULL
a	NULL
retroviral	NULL
vector	NULL
carrying	NULL
the	NULL
human	NULL
ICSBP	NULL
cDNA	NULL
.	NULL

Although	NULL
these	NULL
cells	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
ICSBP	NULL
,	NULL
ICSBP	NULL
expression	NULL
failed	NULL
to	NULL
suppress	NULL
the	NULL
expression	NULL
of	NULL
IRF-1	NULL
,	NULL
p21	NULL
***	NULL
,	NULL
or	NULL
ISGF3y	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
;	NULL
expression	NULL
of	NULL
IRF-1	NULL
was	NULL
slightly	NULL
increased	NULL
in	NULL
cells	NULL
expressing	NULL
ICSBP	NULL
.	NULL

Therefore	NULL
,	NULL
up-regulation	NULL
of	NULL
IRF-1	NULL
,	NULL
ISGF3y	NULL
,	NULL
and	NULL
p21	NULL
WA	NULL
``	NULL
``	NULL
is	NULL
not	NULL
directly	NULL
linked	NULL
to	NULL
reduced	NULL
ICSBP	NULL
expression	NULL
.	NULL

MEFILL	NULL
(	NULL
WT	NULL
)	NULL
-	NULL
MEF6	NULL
(	NULL
FaneC-/	NULL
)	NULL
HSC536N/neo	NULL
HSCS36N/FANCC	NULL
min	NULL
.	NULL

min	NULL
miFNy	NULL
ID	NULL
30	NULL
60	NULL
90	NULL
120	NULL
'	NULL
0	NULL
30	NULL
so	NULL
so	NULL
120	NULL
]	NULL
hIFNYy	NULL
|o	NULL
15	NULL
30	NULL
eo	NULL
solo	NULL
15	NULL
30	NULL
60	NULL
BDâ|	NULL
Am	NULL
wo	NULL
me	NULL
tt	NULL
Figure	NULL
5	NULL
.	NULL

STAT1	NULL
binding	NULL
to	NULL
the	NULL
IRF-1	NULL
GAS	NULL
element	NULL
is	NULL
reduced	NULL
in	NULL
FA-C	NULL
cell	NULL
lines	NULL
.	NULL

EMSA	NULL
of	NULL
STAT1	NULL
binding	NULL
to	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
GAS	NULL
element	NULL
in	NULL
the	NULL
IRF-1	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
IFNy-inducible	NULL
STATA	NULL
binding	NULL
is	NULL
diminished	NULL
in	NULL
FancC'~	NULL
cells	NULL
(	NULL
MEF61	NULL
)	NULL
(	NULL
lanes	NULL
6	NULL
through	NULL
10	NULL
)	NULL
compared	NULL
with	NULL
WT	NULL
MEFs	NULL
(	NULL
MEF11.1	NULL
)	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
5	NULL
)	NULL
.	NULL

Murine	NULL
IFNy	NULL
was	NULL
used	NULL
at	NULL
1	NULL
ng/mL	NULL
at	NULL
37Â°C	NULL
.	NULL

(	NULL
B	NULL
)	NULL
No	NULL
STAT1	NULL
binding	NULL
occurs	NULL
in	NULL
HSC536N/neo	NULL
(	NULL
lanes	NULL
1	NULL
through	NULL
5	NULL
)	NULL
,	NULL
whereas	NULL
in	NULL
HSCS36N/FANCC	NULL
,	NULL
STAT1	NULL
binds	NULL
in	NULL
an	NULL
IFNy-inducible	NULL
manner	NULL
(	NULL
lanes	NULL
6	NULL
through	NULL
10	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
1	NULL
ng/mL	NULL
human	NULL
IFNy	NULL
at	NULL
37Â°C	NULL
.	NULL

FANCC	NULL
SUPPRESSES	NULL
IFNy-INDUCIBLE	NULL
GENE	NULL
EXPRESSION	NULL
_	NULL
3021	NULL
A	NULL
HSC536N/FANCC	NULL
MEFI1.1	NULL
(	NULL
WT	NULL
)	NULL
MEF61	NULL
(	NULL
FancC-/-	NULL
)	NULL
HSC536N/neo	NULL
HSCS536N	NULL
>	NULL
.	NULL

mIFNy	NULL
[	NULL
_o	NULL
2a	NULL
if	NULL
0	NULL
24	NULL
1	NULL
~ICSBP	NULL
seme	NULL
cuses	NULL
.	NULL

cues	NULL
Â«	NULL
am	NULL
Cun	NULL
Guth	NULL
cunt	NULL
duth	NULL
-	NULL
BâTubulin	NULL
1Â°	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Â°	NULL
17	NULL
8	NULL
B	NULL
MEFI1.1	NULL
MEF6I	NULL
(	NULL
WT	NULL
)	NULL
(	NULL
FancC/	NULL
)	NULL
I	NULL
I	NULL
0	NULL
30Â°	NULL
60Â°	NULL
90Â°	NULL
120Â°	NULL
o	NULL
30Â°	NULL
60	NULL
90Â°	NULL
120Â°	NULL
WW	NULL
W	NULL
-	NULL
=	NULL
-~	NULL
mIFNy	NULL
1.9	NULL
â	NULL
!	NULL

14	NULL
%	NULL
3	NULL
4	NULL
5	NULL
60	NULL
17	NULL
8	NULL
9	NULL
10	NULL
Figure	NULL
6	NULL
.	NULL

ICSBP	NULL
is	NULL
expressed	NULL
at	NULL
reduced	NULL
levels	NULL
in	NULL
FA-C	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Immunoblot	NULL
analysis	NULL
demonstrates	NULL
that	NULL
ICSBP	NULL
is	NULL
expressed	NULL
inducibly	NULL
(	NULL
50	NULL
ng/mL	NULL
IFNy	NULL
for	NULL
24	NULL
hours	NULL
)	NULL
in	NULL
wild-type	NULL
MEFs	NULL
(	NULL
MEF11.1	NULL
)	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
at	NULL
high	NULL
levels	NULL
.	NULL

ICSBP	NULL
expression	NULL
in	NULL
the	NULL
'~	NULL
MEF	NULL
line	NULL
(	NULL
MEF61	NULL
)	NULL
is	NULL
significantly	NULL
reduced	NULL
compared	NULL
with	NULL
the	NULL
wild-type	NULL
cells	NULL
(	NULL
lane	NULL
4	NULL
vs	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Constitutive	NULL
expression	NULL
of	NULL
ICSBP	NULL
is	NULL
reduced	NULL
in	NULL
FA-C	NULL
B	NULL
lymphoblasts	NULL
compared	NULL
with	NULL
normal	NULL
and	NULL
corrected	NULL
cells	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
8	NULL
vs	NULL
lanes	NULL
5	NULL
and	NULL
7	NULL
)	NULL
.	NULL

The	NULL
same	NULL
blot	NULL
was	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
-tubulin	NULL
to	NULL
demonstrate	NULL
equivalent	NULL
loading	NULL
(	NULL
lower	NULL
panel	NULL
!	NULL
)	NULL

.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
of	NULL
the	NULL
GAS	NULL
element	NULL
of	NULL
murine	NULL
ICSBP	NULL
demonstrates	NULL
reduced	NULL
IFNy-stimulated	NULL
binding	NULL
in	NULL
FancC/~	NULL
MEFs	NULL
compared	NULL
with	NULL
WT	NULL
MEFs	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
ng/mL	NULL
murine	NULL
IFNy	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

Discussion	NULL
Interferons	NULL
are	NULL
involved	NULL
in	NULL
a	NULL
broad	NULL
range	NULL
of	NULL
mammalian	NULL
biological	NULL
functions	NULL
,	NULL
including	NULL
immunity	NULL
,	NULL
inflammation	NULL
,	NULL
hematopoiesis	NULL
,	NULL
cell	NULL
proliferation	NULL
,	NULL
and	NULL
differentiation	NULL
.	NULL

'*	NULL
'	NULL
``	NULL
In	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
,	NULL
IFNy	NULL
induces	NULL
apoptosis	NULL
,	NULL
``	NULL
``	NULL
*	NULL
``	NULL
%	NULL
4	NULL
``	NULL
and	NULL
there	NULL
is	NULL
compelling	NULL
indirect	NULL
evidence	NULL
that	NULL
it	NULL
plays	NULL
a	NULL
pathophysiologically	NULL
significant	NULL
role	NULL
in	NULL
acquired	NULL
aplastic	NULL
anemias	NULL
.	NULL

``	NULL
``	NULL
``	NULL
``	NULL
2~	NULL
'	NULL
Because	NULL
FA-C	NULL
cells	NULL
are	NULL
hypersensitive	NULL
to	NULL
IFNy	NULL
,	NULL
``	NULL
>	NULL
**	NULL
we	NULL
believe	NULL
that	NULL
IFNy	NULL
hypersensitivity	NULL
and	NULL
bone	NULL
marrow	NULL
failure	NULL
may	NULL
be	NULL
linked	NULL
in	NULL
FA	NULL
.	NULL

Accordingly	NULL
,	NULL
we	NULL
have	NULL
focused	NULL
our	NULL
attention	NULL
on	NULL
the	NULL
IFNy	NULL
signaling	NULL
pathway	NULL
in	NULL
FA-C	NULL
cells	NULL
as	NULL
a	NULL
way	NULL
of	NULL
deciphering	NULL
the	NULL
function	NULL
of	NULL
the	NULL
FANCC	NULL
protein	NULL
in	NULL
modulating	NULL
the	NULL
apoptotic	NULL
response	NULL
to	NULL
extracellular	NULL
cues	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
IFNy	NULL
are	NULL
mediated	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
through	NULL
transcriptional	NULL
regulation	NULL
of	NULL
downstream	NULL
genes	NULL
,	NULL
which	NULL
include	NULL
members	NULL
of	NULL
the	NULL
IRF	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

We	NULL
find	NULL
that	NULL
certain	NULL
IRF	NULL
family	NULL
members	NULL
are	NULL
constitutively	NULL
overexpressed	NULL
in	NULL
specific	NULL
FA-C	NULL
cell	NULL
types	NULL
compared	NULL
with	NULL
normal	NULL
cells	NULL
.	NULL

ISGF3y	NULL
,	NULL
which	NULL
is	NULL
constitutively	NULL
expressed	NULL
at	NULL
higher	NULL
levels	NULL
in	NULL
FANCC	NULL
mutant	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3022	NULL
-	NULL
FAGERLIE	NULL
etal	NULL
HSC536N/neo	NULL
HSCS53GN	NULL
[	NULL
nscssenicssr	NULL
--	NULL
-	NULL
I1CSBP	NULL
M	NULL
--	NULL
IRF	NULL
--	NULL
-	NULL
ISGF3Y	NULL
ma	NULL
me	NULL
aut	NULL
._	NULL
p21	NULL
AC	NULL
1	NULL
2	NULL
3	NULL
Figure	NULL
7	NULL
.	NULL

Enforced	NULL
expression	NULL
of	NULL
ICSBP	NULL
fails	NULL
to	NULL
down-regulate	NULL
IRF-1	NULL
ISGF3y	NULL
or	NULL
p21W4	NULL
``	NULL
!	NULL

.	NULL

Immunoblot	NULL
analysis	NULL
of	NULL
FA-C	NULL
B	NULL
lymphoblasts	NULL
HSCS36N	NULL
(	NULL
lane1	NULL
)	NULL
,	NULL
HSC536N	NULL
transduced	NULL
with	NULL
the	NULL
human	NULL
ICSBP	NULL
cDNA	NULL
(	NULL
HSCS36N/ICSBP	NULL
)	NULL
(	NULL
lane2	NULL
)	NULL
,	NULL
and	NULL
HSC536N	NULL
transduced	NULL
with	NULL
vector	NULL
alone	NULL
(	NULL
HSCS36N/neo	NULL
)	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
demonstrates	NULL
that	NULL
HSC536N/	NULL
ICSBP	NULL
are	NULL
expressing	NULL
high	NULL
constitutive	NULL
levels	NULL
of	NULL
ICSBP	NULL
,	NULL
but	NULL
this	NULL
expression	NULL
fails	NULL
to	NULL
suppress	NULL
IRF-1	NULL
,	NULL
ISGF3y	NULL
,	NULL
or	NULL
p21	NULL
WA	NULL
``	NULL
.	NULL

B	NULL
lymphoblasts	NULL
,	NULL
MEFs	NULL
,	NULL
and	NULL
patient	NULL
LDBMCs	NULL
,	NULL
is	NULL
of	NULL
particular	NULL
interest	NULL
because	NULL
it	NULL
is	NULL
the	NULL
only	NULL
protein	NULL
of	NULL
the	NULL
IRF	NULL
family	NULL
known	NULL
to	NULL
complex	NULL
with	NULL
STAT	NULL
molecules	NULL
.	NULL
``	NULL

ISGF3qy	NULL
exerts	NULL
its	NULL
transcriptional	NULL
activation	NULL
only	NULL
in	NULL
conjunction	NULL
with	NULL
STAT1	NULL
and	NULL
STAT2*	NULL
and	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
IFN-B	NULL
gene	NULL
expression	NULL
,	NULL
``	NULL
a	NULL
finding	NULL
of	NULL
relevance	NULL
because	NULL
some	NULL
researchers	NULL
have	NULL
suggested	NULL
that	NULL
the	NULL
induced	NULL
expression	NULL
of	NULL
IFN-B	NULL
is	NULL
required	NULL
for	NULL
the	NULL
hematopoietic	NULL
suppressive	NULL
effects	NULL
of	NULL
IFNy	NULL
.	NULL

*	NULL
``	NULL
IRF-1	NULL
is	NULL
required	NULL
for	NULL
carrying	NULL
out	NULL
the	NULL
apoptotic	NULL
effects	NULL
of	NULL
IFNy	NULL
signaling	NULL
.	NULL

The	NULL
ratio	NULL
of	NULL
IRFl	NULL
to	NULL
IRF2	NULL
expression	NULL
is	NULL
important	NULL
for	NULL
proper	NULL
cell	NULL
cycle	NULL
control	NULL
.	NULL
``	NULL

''	NULL
IRF-1	NULL
expression	NULL
is	NULL
significantly	NULL
increased	NULL
in	NULL
FA-C	NULL
hematopoietic	NULL
and	NULL
embryonic	NULL
cells	NULL
,	NULL
but	NULL
no	NULL
differences	NULL
in	NULL
IRF-2	NULL
expression	NULL
levels	NULL
were	NULL
found	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
,	NULL
upsetting	NULL
the	NULL
proper	NULL
balance	NULL
of	NULL
IRF-1	NULL
and	NULL
IRF-2	NULL
levels	NULL
in	NULL
FA-C	NULL
cells	NULL
.	NULL

IRF-1	NULL
also	NULL
cooperates	NULL
with	NULL
p53	NULL
to	NULL
induce	NULL
expression	NULL
of	NULL
the	NULL
cdk	NULL
inhibitor	NULL
Although	NULL
equivalent	NULL
p53	NULL
expression	NULL
levels	NULL
were	NULL
found	NULL
between	NULL
FancC-'~	NULL
MEFs	NULL
and	NULL
FancC*	NULL
'	NULL
``	NULL
*	NULL
MEFs	NULL
and	NULL
only	NULL
minimal	NULL
differences	NULL
in	NULL
p53	NULL
expression	NULL
were	NULL
found	NULL
in	NULL
human	NULL
FA-C	NULL
B	NULL
lymphoblasts	NULL
compared	NULL
with	NULL
normal	NULL
cells	NULL
,	NULL
FA-C	NULL
cells	NULL
expressed	NULL
significantly	NULL
greater	NULL
amounts	NULL
of	NULL
p21	NULL
YA	NULL
``	NULL
!	NULL

(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
difference	NULL
in	NULL
p53	NULL
binding	NULL
to	NULL
its	NULL
p21	NULL
WA	NULL
``	NULL
-binding	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
IRF-1	NULL
independent	NULL
edk	NULL
inhibitor	NULL
p27Â°	NULL
``	NULL
``	NULL
was	NULL
equivalent	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
IRF-1	NULL
up-regulation	NULL
contributes	NULL
to	NULL
the	NULL
overexpression	NULL
of	NULL
p21WA	NULL
``	NULL
'	NULL
.	NULL

However	NULL
,	NULL
given	NULL
that	NULL
we	NULL
find	NULL
high	NULL
constitutive	NULL
in	NULL
FA-A	NULL
cells	NULL
and	NULL
that	NULL
these	NULL
cells	NULL
do	NULL
not	NULL
overexpress	NULL
IRF-1	NULL
,	NULL
it	NULL
is	NULL
more	NULL
likely	NULL
that	NULL
up-regulation	NULL
of	NULL
p21WA	NULL
``	NULL
'	NULL
and	NULL
the	NULL
IRF	NULL
BLOOD	NULL
,	NULL
15	NULL
MAY	NULL
2001	NULL
Â«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
10	NULL
transactivators	NULL
may	NULL
be	NULL
due	NULL
to	NULL
abnormalities	NULL
in	NULL
different	NULL
pathways	NULL
,	NULL
one	NULL
of	NULL
which	NULL
is	NULL
influenced	NULL
by	NULL
both	NULL
FANCA	NULL
and	NULL
FANCC	NULL
or	NULL
the	NULL
entire	NULL
FA	NULL
complex	NULL
and	NULL
the	NULL
other	NULL
by	NULL
FANCC	NULL
alone	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
IRF-1	NULL
,	NULL
ISGF3y	NULL
,	NULL
and	NULL
p21	NULL
W*	NULL
,	NULL
others	NULL
have	NULL
found	NULL
that	NULL
IFNy-inducible	NULL
GTPase	NULL
,	NULL
MxA	NULL
,	NULL
which	NULL
confers	NULL
intracellular	NULL
antiviral	NULL
activity	NULL
in	NULL
IFN-induced	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
is	NULL
also	NULL
constitutively	NULL
expressed	NULL
in	NULL
FA	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
a	NULL
finding	NULL
we	NULL
confirm	NULL
here	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
several	NULL
IFNy-inducible	NULL
factors	NULL
that	NULL
are	NULL
important	NULL
in	NULL
regulation	NULL
of	NULL
apoptosis	NULL
and	NULL
mitogenic	NULL
inhibition	NULL
are	NULL
constitutively	NULL
upregulated	NULL
in	NULL
FA-C	NULL
cells	NULL
in	NULL
a	NULL
cell-type-specific	NULL
manner	NULL
.	NULL

Surprisingly	NULL
,	NULL
though	NULL
FA-C	NULL
hematopoietic	NULL
and	NULL
embryonic	NULL
cells	NULL
(	NULL
1	NULL
)	NULL
are	NULL
hypersensitive	NULL
to	NULL
the	NULL
mitotic	NULL
inhibitory	NULL
effects	NULL
of	NULL
IFNy	NULL
and	NULL
(	NULL
2	NULL
)	NULL
express	NULL
constitutively	NULL
high	NULL
levels	NULL
of	NULL
several	NULL
IFNy-inducible	NULL
genes	NULL
(	NULL
effects	NULL
abrogated	NULL
by	NULL
transduction	NULL
of	NULL
normal	NULL
FANCC	NULL
cDNA	NULL
)	NULL
,	NULL
activation	NULL
of	NULL
STAT	NULL
1	NULL
is	NULL
impaired	NULL
.	NULL
``	NULL

''	NULL
We	NULL
sought	NULL
to	NULL
determine	NULL
if	NULL
loss	NULL
of	NULL
STAT1	NULL
activation	NULL
occurs	NULL
only	NULL
in	NULL
those	NULL
cell	NULL
types	NULL
exhibiting	NULL
high	NULL
constitutive	NULL
expression	NULL
of	NULL
IFNy-inducible	NULL
genes	NULL
.	NULL

We	NULL
found	NULL
STAT1	NULL
phosphorylation	NULL
to	NULL
be	NULL
defective	NULL
in	NULL
FA-C	NULL
B	NULL
lymphoblasts	NULL
and	NULL
MEFs	NULL
,	NULL
but	NULL
not	NULL
in	NULL
mature	NULL
human	NULL
fibroblasts	NULL
(	NULL
Figures	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Because	NULL
mature	NULL
human	NULL
fibroblasts	NULL
do	NULL
not	NULL
overexpress	NULL
these	NULL
genes	NULL
,	NULL
we	NULL
reason	NULL
that	NULL
the	NULL
overexpression	NULL
of	NULL
IRF-1	NULL
,	NULL
ISGF3y	NULL
,	NULL
and	NULL
p21WA	NULL
``	NULL
!	NULL

occurs	NULL
only	NULL
in	NULL
FA-C	NULL
cells	NULL
defective	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
activate	NULL
STAT1	NULL
.	NULL

Up-regulation	NULL
of	NULL
these	NULL
genes	NULL
in	NULL
these	NULL
cells	NULL
appears	NULL
to	NULL
require	NULL
that	NULL
(	NULL
1	NULL
)	NULL
FANCC	NULL
be	NULL
inactivated	NULL
and	NULL
(	NULL
2	NULL
)	NULL
the	NULL
particular	NULL
FANCC	NULL
mutation	NULL
suppress	NULL
STAT1	NULL
activation	NULL
.	NULL

Therefore	NULL
,	NULL
constitutive	NULL
expression	NULL
of	NULL
IFNy-responsive	NULL
genes	NULL
in	NULL
FANCC	NULL
mutant	NULL
cells	NULL
is	NULL
due	NULL
to	NULL
either	NULL
ground-state	NULL
activation	NULL
of	NULL
a	NULL
pathway	NULL
that	NULL
does	NULL
not	NULL
require	NULL
STAT1	NULL
phosphorylation	NULL
or	NULL
loss	NULL
of	NULL
a	NULL
hematopoietic	NULL
IFNy-responsive	NULL
protein	NULL
that	NULL
normally	NULL
modulates	NULL
expression	NULL
of	NULL
other	NULL
IFN-responsive	NULL
genes	NULL
.	NULL

One	NULL
IFNy-responsive	NULL
modulator	NULL
of	NULL
interest	NULL
to	NULL
us	NULL
was	NULL
the	NULL
transcriptional	NULL
repressor	NULL
ICSBP	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
IRF	NULL
family	NULL
expressed	NULL
mainly	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL
``	NULL

ICSBP	NULL
interacts	NULL
with	NULL
both	NULL
IREF-1	NULL
and	NULL
IRF-2	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
and	NULL
inhibits	NULL
the	NULL
DNA-binding	NULL
activity	NULL
of	NULL
ISGF3y	NULL
.	NULL
``	NULL

''	NULL
ICSBP	NULL
binds	NULL
to	NULL
IRF-1	NULL
and	NULL
suppresses	NULL
some	NULL
IFNy-induced	NULL
gene	NULL
responses	NULL
.	NULL
``	NULL

Stable	NULL
expression	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
ICSBP	NULL
blocks	NULL
IRF-1	NULL
transactivation	NULL
and	NULL
also	NULL
inhibits	NULL
binding	NULL
of	NULL
STAT1	NULL
to	NULL
GAS	NULL
.	NULL
``	NULL

In	NULL
FANCC	NULL
mutant	NULL
B	NULL
lymphoblasts	NULL
we	NULL
found	NULL
less	NULL
ICSBP	NULL
expression	NULL
than	NULL
normal	NULL
cells	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
ICSBP	NULL
is	NULL
the	NULL
only	NULL
IFNy-inducible	NULL
protein	NULL
of	NULL
those	NULL
we	NULL
have	NULL
tested	NULL
that	NULL
is	NULL
reduced	NULL
in	NULL
FA-C	NULL
cells	NULL
.	NULL

Surprisingly	NULL
,	NULL
ICSBP	NULL
is	NULL
also	NULL
expressed	NULL
in	NULL
an	NULL
inducible	NULL
manner	NULL
in	NULL
MEFs	NULL
,	NULL
and	NULL
this	NULL
expression	NULL
is	NULL
significantly	NULL
reduced	NULL
in	NULL
FancC	NULL
mutant	NULL
MEFs	NULL
.	NULL

We	NULL
first	NULL
hypothesized	NULL
that	NULL
low	NULL
expression	NULL
levels	NULL
of	NULL
ICSBP	NULL
in	NULL
FA-C	NULL
cells	NULL
may	NULL
be	NULL
a	NULL
direct	NULL
result	NULL
of	NULL
a	NULL
deficiency	NULL
in	NULL
STAT1	NULL
phosphorylation	NULL
in	NULL
FA-C	NULL
cells	NULL
.	NULL

Indeed	NULL
,	NULL
STAT1	NULL
binding	NULL
to	NULL
the	NULL
GAS	NULL
element	NULL
from	NULL
ICSBP	NULL
is	NULL
significantly	NULL
reduced	NULL
in	NULL
FA-C	NULL
cells	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

Because	NULL
ICSBP	NULL
is	NULL
decreased	NULL
in	NULL
those	NULL
cells	NULL
with	NULL
up-regulated	NULL
IFNy-inducible	NULL
genes	NULL
,	NULL
we	NULL
next	NULL
reasoned	NULL
that	NULL
loss	NULL
of	NULL
ICSBP	NULL
contributes	NULL
to	NULL
the	NULL
up-regulation	NULL
of	NULL
these	NULL
genes	NULL
.	NULL

However	NULL
,	NULL
enforced	NULL
expression	NULL
of	NULL
ICSBP	NULL
into	NULL
these	NULL
cells	NULL
failed	NULL
to	NULL
down-regulate	NULL
IRF-1	NULL
,	NULL
ISGF3y	NULL
,	NULL
or	NULL
p21	NULL
``	NULL
W4	NULL
``	NULL
'	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
up-regulation	NULL
of	NULL
these	NULL
IFN	NULL
y-inducible	NULL
factors	NULL
in	NULL
FA	NULL
cells	NULL
is	NULL
not	NULL
directly	NULL
linked	NULL
with	NULL
reduced	NULL
ICSBP	NULL
expression	NULL
levels	NULL
.	NULL

FA	NULL
cells	NULL
,	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
,	NULL
are	NULL
not	NULL
hardy	NULL
.	NULL

They	NULL
grow	NULL
slowly	NULL
and	NULL
have	NULL
a	NULL
high	NULL
apoptotic	NULL
fraction	NULL
.	NULL
``	NULL

Studies	NULL
in	NULL
our	NULL
laboratory	NULL
have	NULL
focused	NULL
,	NULL
in	NULL
large	NULL
part	NULL
,	NULL
on	NULL
clarifying	NULL
molecular	NULL
determinants	NULL
of	NULL
the	NULL
death	NULL
pathways	NULL
in	NULL
FA	NULL
cells	NULL
and	NULL
on	NULL
beginning	NULL
to	NULL
establish	NULL
an	NULL
ordered	NULL
relationship	NULL
of	NULL
these	NULL
death	NULL
pathways	NULL
to	NULL
discrete	NULL
FA	NULL
proteins	NULL
.	NULL

We	NULL
have	NULL
identified	NULL
roles	NULL
for	NULL
the	NULL
fas/fas-ligand	NULL
pathway	NULL
,	NULL
``	NULL
caspases	NULL
8	NULL
and	NULL
3	NULL
,	NULL
``	NULL
and	NULL
the	NULL
double-stranded	NULL
RNA-dependent	NULL
protein	NULL
kinase	NULL
.	NULL
``	NULL

''	NULL
In	NULL
this	NULL
work	NULL
,	NULL
although	NULL
we	NULL
can	NULL
not	NULL
yet	NULL
clarify	NULL
the	NULL
cause	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
even	NULL
without	NULL
being	NULL
exposed	NULL
to	NULL
BLOOD	NULL
,	NULL
15	NULL
MAY	NULL
2001	NULL
Â«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
10	NULL
environmental	NULL
cues	NULL
for	NULL
apoptosis	NULL
or	NULL
mitotic	NULL
arrest	NULL
,	NULL
at	NULL
a	NULL
gene-expression	NULL
level	NULL
,	NULL
FA-C	NULL
cells	NULL
act	NULL
as	NULL
if	NULL
they	NULL
have	NULL
been	NULL
stimulated	NULL
by	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

FANCC	NULL
SUPPRESSES	NULL
IFNy-INDUCIBLE	NULL
GENE	NULL
EXPRESSION	NULL
such	NULL
factors	NULL
.	NULL

This	NULL
is	NULL
similar	NULL
to	NULL
another	NULL
chromosomal	NULL
instability	NULL
syndrome	NULL
,	NULL
ataxia	NULL
telangiectasia	NULL
(	NULL
AT	NULL
)	NULL
.	NULL

AT	NULL
cells	NULL
are	NULL
hypersensitive	NULL
to	NULL
y	NULL
irradiation	NULL
and	NULL
constitutively	NULL
overexpress	NULL
several	NULL
y-irradiation-	NULL
3023	NULL
hypersensitive	NULL
to	NULL
both	NULL
biological	NULL
and	NULL
chemical	NULL
inducers	NULL
of	NULL
apoptosis	NULL
and	NULL
may	NULL
reveal	NULL
clearer	NULL
functions	NULL
for	NULL
the	NULL
FANCC	NULL
gene	NULL
product	NULL
.	NULL

inducible	NULL
factors	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
In	NULL
view	NULL
of	NULL
the	NULL
apoptotic	NULL
and	NULL
mitogenic	NULL
inhibitory	NULL
activities	NULL
of	NULL
these	NULL
proteins	NULL
,	NULL
we	NULL
suggest	NULL
that	NULL
they	NULL
contribute	NULL
to	NULL
the	NULL
characteristic	NULL
apoptotic	NULL
phenotype	NULL
in	NULL
FA	NULL
bone	NULL
marrow	NULL
cells	NULL
and	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
IFN-hypersensitive	NULL
phenotype	NULL
by	NULL
specifically	NULL
setting	NULL
ground-state	NULL
levels	NULL
of	NULL
these	NULL
proteins	NULL
that	NULL
are	NULL
higher	NULL
than	NULL
those	NULL
in	NULL
normal	NULL
cells	NULL
.	NULL

Clarification	NULL
of	NULL
the	NULL
signaling	NULL
pathways	NULL
by	NULL
which	NULL
aberrantly	NULL
expressed	NULL
genes	NULL
are	NULL
controlled	NULL
in	NULL
FA-C	NULL
cells	NULL
should	NULL
lead	NULL
to	NULL
an	NULL
understanding	NULL
of	NULL
why	NULL
such	NULL
cells	NULL
are	NULL
References	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

Acknowledgments	NULL
The	NULL
authors	NULL
thank	NULL
Dr	NULL
Ben-Zion	NULL
Levi	NULL
for	NULL
kindly	NULL
providing	NULL
the	NULL
human	NULL
ICSBP	NULL
cDNA	NULL
;	NULL
Dr	NULL
Markus	NULL
Grompe	NULL
,	NULL
Dr	NULL
Petra	NULL
Jakobs	NULL
,	NULL
Dr	NULL
Yasmine	NULL
Akarri	NULL
,	NULL
and	NULL
Dr	NULL
Barbara	NULL
Cox	NULL
for	NULL
providing	NULL
the	NULL
human	NULL
FA	NULL
fibroblasts	NULL
;	NULL
Dr	NULL
Manuel	NULL
Buchwald	NULL
for	NULL
the	NULL
HSC536N	NULL
cell	NULL
line	NULL
;	NULL
Dr	NULL
Chris	NULL
Walsh	NULL
for	NULL
the	NULL
HSC72	NULL
and	NULL
HSC72/FANCA	NULL
cell	NULL
lines	NULL
;	NULL
Tara	NULL
Koretsky	NULL
and	NULL
Keaney	NULL
Rathbun	NULL
for	NULL
technical	NULL
support	NULL
;	NULL
and	NULL
Dr	NULL
Qishen	NULL
Pang	NULL
for	NULL
experimental	NULL
help	NULL
and	NULL
advice	NULL
.	NULL

.	NULL

Schroeder	NULL
TM	NULL
,	NULL
Tilgen	NULL
D	NULL
,	NULL
Kruger	NULL
J	NULL
,	NULL
Vogel	NULL
!	NULL

F.	NULL
For	NULL
mal	NULL
genetics	NULL
of	NULL
Fanconi	NULL
's	NULL
anemia	NULL
.	NULL

Hum	NULL
Genet	NULL
.	NULL

1976	NULL
;	NULL
32:257-288	NULL
.	NULL

Liu	NULL
JM	NULL
,	NULL
Buchwald	NULL
M	NULL
,	NULL
Walsh	NULL
CE	NULL
,	NULL
Young	NULL
NS	NULL
.	NULL

Fanconi	NULL
anemia	NULL
and	NULL
novel	NULL
strategies	NULL
for	NULL
therapy	NULL
.	NULL

Blood	NULL
.	NULL

1994	NULL
;	NULL
84:3995-4007	NULL
.	NULL

Auerbach	NULL
AD	NULL
,	NULL
Allen	NULL
RG	NULL
.	NULL

Leukemia	NULL
and	NULL
preleuke-mia	NULL
in	NULL
Fanconi	NULL
anemia	NULL
patients	NULL
:	NULL
a	NULL
review	NULL
of	NULL
the	NULL
literature	NULL
and	NULL
report	NULL
of	NULL
the	NULL
International	NULL
Fanconi	NULL
Anemia	NULL
Registry	NULL
.	NULL

Cancer	NULL
Genet	NULL
Cytogenet	NULL
.	NULL

1991	NULL
;	NULL
51:1-12	NULL
.	NULL

Butturini	NULL
A	NULL
,	NULL
Gale	NULL
RP	NULL
,	NULL
Verlander	NULL
PC	NULL
,	NULL
Adler-Brecher	NULL
B	NULL
,	NULL
Gillio	NULL
AP	NULL
,	NULL
Auerbach	NULL
AD	NULL
.	NULL

Hematologic	NULL
abnormalities	NULL
in	NULL
Fanconi	NULL
anemia	NULL
:	NULL
an	NULL
International	NULL
Fanconi	NULL
Anemia	NULL
Registry	NULL
study	NULL
.	NULL

Blood	NULL
.	NULL

1994	NULL
;	NULL
84	NULL
:	NULL
1650-1655	NULL
.	NULL

Auerbach	NULL
AD	NULL
,	NULL
Rogatko	NULL
A	NULL
,	NULL
Schroeder-Kurth	NULL
TM	NULL
.	NULL

International	NULL
Fanconi	NULL
Anemia	NULL
Registry	NULL
:	NULL
relation	NULL
of	NULL
clinical	NULL
symptoms	NULL
to	NULL
diepoxybutane	NULL
sensitivity	NULL
.	NULL

Blood	NULL
.	NULL

1989	NULL
;	NULL
73:391-396	NULL
.	NULL

Auerbach	NULL
AD	NULL
,	NULL
Adler	NULL
B	NULL
,	NULL
Chaganti	NULL
RS	NULL
.	NULL

Prenatal	NULL
and	NULL
postnatal	NULL
diagnosis	NULL
and	NULL
carrier	NULL
detection	NULL
of	NULL
Fanconi	NULL
anemia	NULL
by	NULL
a	NULL
cytogenetic	NULL
method	NULL
.	NULL

Pediat-rics	NULL
.	NULL

1981	NULL
;	NULL
67:128-135	NULL
.	NULL

Joenje	NULL
H	NULL
,	NULL
Oostra	NULL
AB	NULL
,	NULL
Wijker	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Evidence	NULL
for	NULL
at	NULL
least	NULL
eight	NULL
Fanconi	NULL
anemia	NULL
genes	NULL
.	NULL

Am	NULL
J	NULL
Hum	NULL
Genet	NULL
.	NULL

1997	NULL
;	NULL
61:940-944	NULL
.	NULL

Joenje	NULL
H	NULL
,	NULL
Levitus	NULL
M	NULL
,	NULL
Waisfisz	NULL
Q	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Complementation	NULL
analysis	NULL
in	NULL
Fanconi	NULL
anemia	NULL
:	NULL
assignment	NULL
of	NULL
the	NULL
reference	NULL
FA-H	NULL
patient	NULL
to	NULL
group	NULL
A	NULL
.	NULL

Am	NULL
J	NULL
Hum	NULL
Genet	NULL
.	NULL

2000	NULL
;	NULL
67:759-762	NULL
.	NULL

Strathdee	NULL
CA	NULL
,	NULL
Gavish	NULL
H	NULL
,	NULL
Shannon	NULL
WR	NULL
,	NULL
Buchwald	NULL
M.	NULL
Cloning	NULL
of	NULL
cDNAs	NULL
for	NULL
Fanconi	NULL
's	NULL
anaemia	NULL
by	NULL
functional	NULL
complementation	NULL
.	NULL

Nature	NULL
.	NULL

1992	NULL
;	NULL
356:763-767	NULL
.	NULL

Lo	NULL
TFJ	NULL
,	NULL
Rocimans	NULL
MA	NULL
,	NULL
Bosnoyan-Collins	NULL
L	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Expression	NULL
cloning	NULL
of	NULL
a	NULL
cDNA	NULL
for	NULL
the	NULL
major	NULL
Fanconi	NULL
anaemia	NULL
gene	NULL
,	NULL
FAA	NULL
.	NULL

Nat	NULL
Genet	NULL
.	NULL

1996	NULL
;	NULL
14	NULL
:	NULL
320-323.	NULL
de	NULL
Winter	NULL
JP	NULL
et	NULL
al	NULL
.	NULL

The	NULL
Fanconi	NULL
Anaemia	NULL
group	NULL
G	NULL
gene	NULL
FANCG	NULL
is	NULL
identical	NULL
with	NULL
XRCC9	NULL
.	NULL

Nat	NULL
Genet	NULL
.	NULL

1998	NULL
;	NULL
20:281-283.	NULL
de	NULL
Winter	NULL
JP	NULL
,	NULL
Rocimans	NULL
MA	NULL
,	NULL
van	NULL
Der	NULL
Weel	NULL
,	NULL
et	NULL
al	NULL
.	NULL

The	NULL
Fanconi	NULL
anaemia	NULL
gene	NULL
FANCF	NULL
encodes	NULL
a	NULL
novel	NULL
protein	NULL
with	NULL
homology	NULL
to	NULL
ROM	NULL
.	NULL

Nat	NULL
Genet	NULL
.	NULL

2000	NULL
;	NULL
24:15-16.	NULL
de	NULL
Winter	NULL
JP	NULL
,	NULL
Leveille	NULL
F	NULL
,	NULL
van	NULL
Berkel	NULL
CG	NULL
,	NULL
etal	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
cDNA	NULL
representing	NULL
the	NULL
Fanconi	NULL
anemia	NULL
complementation	NULL
group	NULL
E	NULL
gene	NULL
.	NULL

Am	NULL
J	NULL
Hum	NULL
Genet	NULL
.	NULL

2000	NULL
;	NULL
67:1306-1308	NULL
.	NULL

Youssoufian	NULL
H.	NULL
Cytoplasmic	NULL
localization	NULL
of	NULL
FAC	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
correction	NULL
of	NULL
a	NULL
prerepair	NULL
defect	NULL
in	NULL
Fanconi	NULL
anemia	NULL
group	NULL
C	NULL
cells	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

1996	NULL
;	NULL
97:2003-2010	NULL
.	NULL

Yamashita	NULL
T	NULL
,	NULL
Wu	NULL
N	NULL
,	NULL
Kupfer	NULL
G	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Clinical	NULL
variability	NULL
of	NULL
Fanconi	NULL
anemia	NULL
(	NULL
type	NULL
C	NULL
)	NULL
results	NULL
from	NULL
expression	NULL
of	NULL
an	NULL
amino	NULL
terminal	NULL
truncated	NULL
Fanconi	NULL
anemia	NULL
complementation	NULL
group	NULL
C	NULL
polypep-tide	NULL
with	NULL
partial	NULL
activity	NULL
.	NULL

Blood	NULL
.	NULL

1996	NULL
;	NULL
87:4424-4432	NULL
.	NULL

16	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

286	NULL
.	NULL

29	NULL
.	NULL

Pestka	NULL
S	NULL
,	NULL
Langer	NULL
JA	NULL
,	NULL
Zoon	NULL
KC	NULL
.	NULL

Interferons	NULL
and	NULL
their	NULL
actions	NULL
.	NULL

Annu	NULL
Rev	NULL
Biochem	NULL
.	NULL

1987	NULL
;	NULL
56:727-777.	NULL
.	NULL

Zoumbos	NULL
NC	NULL
,	NULL
Gascon	NULL
P	NULL
,	NULL
Djeu	NULL
JY	NULL
,	NULL
Young	NULL
NS	NULL
.	NULL

In	NULL
terferon	NULL
is	NULL
a	NULL
mediator	NULL
of	NULL
hematopoietic	NULL
suppression	NULL
in	NULL
aplastic	NULL
anemia	NULL
in	NULL
vitro	NULL
and	NULL
possibly	NULL
in	NULL
vivo	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1985	NULL
;	NULL
82:188-192.	NULL
.	NULL

Sato	NULL
T	NULL
,	NULL
Selleri	NULL
C	NULL
,	NULL
Young	NULL
NS	NULL
,	NULL
Maciejewski	NULL
JP	NULL
.	NULL

He	NULL
matopoietic	NULL
inhibition	NULL
by	NULL
interferon-gamma	NULL
is	NULL
partially	NULL
mediated	NULL
through	NULL
interferon	NULL
regulatory	NULL
fac-tor-1	NULL
.	NULL

Blood	NULL
.	NULL

1995	NULL
;	NULL
86:3373-3380.	NULL
.	NULL

Nakao	NULL
S	NULL
,	NULL
Yamaguchi	NULL
M	NULL
,	NULL
Shiobara	NULL
S	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Inter	NULL
feron-gamma	NULL
gene	NULL
expression	NULL
in	NULL
unstimulated	NULL
bone	NULL
marrow	NULL
mononuclear	NULL
cells	NULL
predicts	NULL
a	NULL
good	NULL
response	NULL
to	NULL
cyclosporine	NULL
therapy	NULL
in	NULL
aplastic	NULL
anemia	NULL
.	NULL

Blood	NULL
.	NULL

1992	NULL
;	NULL
79:2532-2535	NULL
.	NULL

Nistico	NULL
A	NULL
,	NULL
Young	NULL
NS	NULL
.	NULL

gamma-Interferon	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
of	NULL
patients	NULL
with	NULL
aplastic	NULL
anemia	NULL
.	NULL

Ann	NULL
Intern	NULL
Med	NULL
.	NULL

1994	NULL
;	NULL
120:463-469	NULL
.	NULL

Maciejewski	NULL
JP	NULL
,	NULL
Selleri	NULL
C	NULL
,	NULL
Sato	NULL
T	NULL
,	NULL
Anderson	NULL
S	NULL
,	NULL
Young	NULL
NS	NULL
.	NULL

A	NULL
severe	NULL
and	NULL
consistent	NULL
deficit	NULL
in	NULL
marrow	NULL
and	NULL
circulating	NULL
primitive	NULL
hematopoietic	NULL
cells	NULL
{	NULL
long-term	NULL
culture-initiating	NULL
cells	NULL
)	NULL
in	NULL
acquired	NULL
aplastic	NULL
anemia	NULL
.	NULL

Blood	NULL
.	NULL

1996	NULL
;	NULL
88:1983-1991	NULL
.	NULL

Selleri	NULL
C	NULL
,	NULL
Maciejewski	NULL
JP	NULL
,	NULL
Sato	NULL
T	NULL
,	NULL
Young	NULL
NS	NULL
.	NULL

Interferon-gamma	NULL
constitutively	NULL
expressed	NULL
in	NULL
the	NULL
stromal	NULL
microenvironment	NULL
of	NULL
human	NULL
marrow	NULL
cultures	NULL
mediates	NULL
potent	NULL
hematopoietic	NULL
inhibition	NULL
.	NULL

Blood	NULL
.	NULL

1996	NULL
;	NULL
87:4149-4157	NULL
.	NULL

Whitney	NULL
MA	NULL
,	NULL
Royle	NULL
G	NULL
,	NULL
Low	NULL
MJ	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Germ	NULL
cell	NULL
defects	NULL
and	NULL
hematopoietic	NULL
hypersensitivity	NULL
to	NULL
gamma-interferon	NULL
in	NULL
mice	NULL
with	NULL
a	NULL
targeted	NULL
disruption	NULL
of	NULL
the	NULL
Fanconi	NULL
anemia	NULL
C	NULL
gene	NULL
.	NULL

Blood	NULL
.	NULL

1996	NULL
;	NULL
88:49-58	NULL
.	NULL

Rathbun	NULL
RK	NULL
,	NULL
Faulkner	NULL
GR	NULL
,	NULL
Ostroski	NULL
MH	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Inactivation	NULL
of	NULL
the	NULL
Fanconi	NULL
anemia	NULL
group	NULL
C	NULL
gene	NULL
augments	NULL
interferon-gamma-induced	NULL
apoptotic	NULL
responses	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Blood	NULL
.	NULL

1997	NULL
;	NULL
90:974-985	NULL
.	NULL

Selleri	NULL
C	NULL
,	NULL
Sato	NULL
T	NULL
,	NULL
Anderson	NULL
S	NULL
,	NULL
Young	NULL
NS	NULL
,	NULL
Maciejewski	NULL
JP	NULL
.	NULL

Interferon-gamma	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor-alpha	NULL
suppress	NULL
both	NULL
early	NULL
and	NULL
late	NULL
stages	NULL
of	NULL
hematopoiesis	NULL
and	NULL
induce	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

J	NULL
Cell	NULL
Physiol	NULL
.	NULL

1995	NULL
;	NULL
165:538-546	NULL
.	NULL

Maciejewski	NULL
J	NULL
,	NULL
Selleri	NULL
C	NULL
,	NULL
Anderson	NULL
S	NULL
,	NULL
Young	NULL
NS	NULL
.	NULL

Fas	NULL
antigen	NULL
expression	NULL
on	NULL
CD34+	NULL
human	NULL
marrow	NULL
cells	NULL
is	NULL
induced	NULL
by	NULL
interferon	NULL
gamma	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
and	NULL
potentiates	NULL
cyto-kine-mediated	NULL
hematopoietic	NULL
suppression	NULL
in	NULL
vitro	NULL
.	NULL

Blood	NULL
.	NULL

1995	NULL
;	NULL
85:3183-3190	NULL
.	NULL

Shuai	NULL
K	NULL
,	NULL
Schindler	NULL
C	NULL
,	NULL
Prezioso	NULL
VR	NULL
,	NULL
Darnell	NULL
JEJ	NULL
.	NULL

Activation	NULL
of	NULL
transcription	NULL
by	NULL
IFN-gamma	NULL
:	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
91-kD	NULL
DNA	NULL
binding	NULL
protein	NULL
.	NULL

Science	NULL
.	NULL

1992	NULL
;	NULL
258:1808-1812	NULL
.	NULL

Darnell	NULL
JEJ	NULL
,	NULL
Kerr	NULL
IM	NULL
,	NULL
Stark	NULL
GR	NULL
.	NULL

Jak-STAT	NULL
pathways	NULL
and	NULL
transcriptional	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
IFNs	NULL
and	NULL
other	NULL
extracellular	NULL
signaling	NULL
proteins	NULL
.	NULL

Science	NULL
.	NULL

1994	NULL
;	NULL
264:1415-1421	NULL
.	NULL

Pang	NULL
Q	NULL
,	NULL
Fagerlie	NULL
S	NULL
,	NULL
Christianson	NULL
TA	NULL
,	NULL
et	NULL
al	NULL
.	NULL

The	NULL
Fanconi	NULL
anemia	NULL
protein	NULL
FANCC	NULL
binds	NULL
to	NULL
and	NULL
fa	NULL
30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42.	NULL
cilitates	NULL
the	NULL
activation	NULL
of	NULL
STATA	NULL
by	NULL
gamma	NULL
interferon	NULL
and	NULL
hematopoietic	NULL
growth	NULL
factors	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

2000	NULL
;	NULL
20:4724-4735	NULL
.	NULL

Saito	NULL
H	NULL
,	NULL
Hammond	NULL
AT	NULL
,	NULL
Moses	NULL
RE	NULL
.	NULL

Hypersensitivity	NULL
to	NULL
oxygen	NULL
is	NULL
a	NULL
uniform	NULL
and	NULL
secondary	NULL
defect	NULL
in	NULL
Fanconi	NULL
anemia	NULL
cells	NULL
.	NULL

Mutat	NULL
Res	NULL
.	NULL

1993	NULL
;	NULL
294:255-262	NULL
.	NULL

Jakobs	NULL
PM	NULL
,	NULL
Sahaayaruban	NULL
P	NULL
,	NULL
Saito	NULL
H	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Im-mortalization	NULL
of	NULL
four	NULL
new	NULL
Fanconi	NULL
anemia	NULL
fibroblast	NULL
cell	NULL
lines	NULL
by	NULL
an	NULL
improved	NULL
procedure	NULL
.	NULL

Somat	NULL
Cell	NULL
Mol	NULL
Genet	NULL
.	NULL

1996	NULL
;	NULL
22:151-157	NULL
.	NULL

Dignam	NULL
JD	NULL
,	NULL
Lebovitz	NULL
RM	NULL
,	NULL
Roeder	NULL
RG	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

1983	NULL
;	NULL
11:1475-1489	NULL
.	NULL

Laemmli	NULL
UK	NULL
.	NULL

Cleavage	NULL
of	NULL
structural	NULL
proteins	NULL
during	NULL
the	NULL
assembly	NULL
of	NULL
the	NULL
head	NULL
of	NULL
bacteriophage	NULL
T4	NULL
.	NULL

Nature	NULL
.	NULL

1970	NULL
;	NULL
227:680-685	NULL
.	NULL

Towbin	NULL
H	NULL
,	NULL
Staghelin	NULL
T	NULL
,	NULL
Gordon	NULL
J.	NULL
Electrophoretic	NULL
transfer	NULL
of	NULL
proteins	NULL
from	NULL
polyacrylamide	NULL
gels	NULL
to	NULL
nitrocellulose	NULL
sheets	NULL
:	NULL
procedure	NULL
and	NULL
some	NULL
appli-cations	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1979	NULL
;	NULL
76:4350-4354	NULL
.	NULL

Tanaka	NULL
N	NULL
,	NULL
Ishihara	NULL
M	NULL
,	NULL
Lamphier	NULL
MS	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cooperation	NULL
of	NULL
the	NULL
tumour	NULL
suppressors	NULL
IRF-1	NULL
and	NULL
p53	NULL
in	NULL
response	NULL
to	NULL
DNA	NULL
damage	NULL
.	NULL

Nature	NULL
.	NULL

1996	NULL
;	NULL
382	NULL
:	NULL
816-818	NULL
.	NULL

Chin	NULL
YE	NULL
,	NULL
Kitagawa	NULL
M	NULL
,	NULL
Su	NULL
WC	NULL
,	NULL
You	NULL
ZH	NULL
,	NULL
Iwamoto	NULL
Y	NULL
,	NULL
Fu	NULL
XY	NULL
.	NULL

Cell	NULL
growth	NULL
arrest	NULL
and	NULL
induction	NULL
of	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
p21	NULL
WAF1/CIP1	NULL
mediated	NULL
by	NULL
STAT1	NULL
.	NULL

Science	NULL
.	NULL

1996	NULL
;	NULL
272:719-722	NULL
.	NULL

Bovolenta	NULL
C	NULL
,	NULL
Driggers	NULL
PH	NULL
,	NULL
Marks	NULL
MS	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Molecular	NULL
interactions	NULL
between	NULL
interferon	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
and	NULL
members	NULL
of	NULL
the	NULL
interferon	NULL
regulatory	NULL
factor	NULL
family	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sei	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1994	NULL
;	NULL
91:5046-5050	NULL
.	NULL

Nelson	NULL
N	NULL
,	NULL
Marks	NULL
MS	NULL
,	NULL
Driggers	NULL
PH	NULL
,	NULL
Ozato	NULL
K.	NULL
Interferon	NULL
consensus	NULL
sequence-binding	NULL
protein	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
interferon	NULL
regulatory	NULL
factor	NULL
family	NULL
,	NULL
suppresses	NULL
interferon-induced	NULL
gene	NULL
transcrip-tion	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1993	NULL
;	NULL
13:588-599	NULL
.	NULL

Nelson	NULL
N	NULL
,	NULL
Kanno	NULL
Y	NULL
,	NULL
Hong	NULL
C	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Expression	NULL
of	NULL
IFN	NULL
regulatory	NULL
factor	NULL
family	NULL
proteins	NULL
in	NULL
lympho-cytes	NULL
.	NULL

Induction	NULL
of	NULL
Stat-1	NULL
and	NULL
IFN	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
expression	NULL
by	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
156:3711-3720	NULL
.	NULL

Dai	NULL
CH	NULL
,	NULL
Price	NULL
JO	NULL
,	NULL
Brunner	NULL
T	NULL
,	NULL
Krantz	NULL
SB	NULL
.	NULL

Fas	NULL
li-gand	NULL
is	NULL
present	NULL
in	NULL
human	NULL
erythroid	NULL
colony-forming	NULL
cells	NULL
and	NULL
interacts	NULL
with	NULL
Fas	NULL
induced	NULL
by	NULL
interferon	NULL
gamma	NULL
to	NULL
produce	NULL
erythroid	NULL
cell	NULL
apoptosis	NULL
.	NULL

Blood	NULL
.	NULL

1998	NULL
;	NULL
91:1235-1242	NULL
.	NULL

Maciejewski	NULL
JP	NULL
,	NULL
Selleri	NULL
C	NULL
,	NULL
Sato	NULL
T	NULL
,	NULL
Anderson	NULL
S	NULL
,	NULL
Young	NULL
NS	NULL
.	NULL

Increased	NULL
expression	NULL
of	NULL
Fas	NULL
antigen	NULL
on	NULL
bone	NULL
marrow	NULL
CD34+	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
aplastic	NULL
anaemia	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
.	NULL

1995	NULL
;	NULL
91:245-252	NULL
.	NULL

Qureshi	NULL
SA	NULL
,	NULL
Salditt-Georgieff	NULL
M	NULL
,	NULL
Darnell	NULL
JEJ	NULL
.	NULL

Ty-rosine-phosphorylated	NULL
Stati	NULL
and	NULL
Stat	NULL
?	NULL

plus	NULL
a	NULL
48-kDa	NULL
protein	NULL
all	NULL
contact	NULL
DNA	NULL
in	NULL
forming	NULL
interferon-stimulated-gene	NULL
factor	NULL
3	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1995	NULL
;	NULL
92:3829-3833	NULL
.	NULL

3024	NULL
43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

FAGERLIE	NULL
et	NULL
al	NULL
Veals	NULL
SA	NULL
,	NULL
Schindler	NULL
C	NULL
,	NULL
Leonard	NULL
D	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Subunit	NULL
of	NULL
an	NULL
alpha-interferon-responsive	NULL
transcription	NULL
factor	NULL
is	NULL
related	NULL
to	NULL
interferon	NULL
regulatory	NULL
factor	NULL
and	NULL
Myb	NULL
families	NULL
of	NULL
DNA-binding	NULL
proteins	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1992	NULL
;	NULL
12:3315-3324	NULL
.	NULL

Kawakami	NULL
T	NULL
,	NULL
Matsumoto	NULL
M	NULL
,	NULL
Sato	NULL
M	NULL
,	NULL
Harada	NULL
H	NULL
,	NULL
Taniguchi	NULL
T	NULL
,	NULL
Kitagawa	NULL
M.	NULL
Possible	NULL
involvement	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
ISGF3	NULL
gamma	NULL
in	NULL
virus-induced	NULL
expression	NULL
of	NULL
the	NULL
IFN-beta	NULL
gene	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

1995	NULL
;	NULL
358:225-229	NULL
.	NULL

Harada	NULL
H	NULL
,	NULL
Matsumoto	NULL
M	NULL
,	NULL
Sato	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Regulation	NULL
of	NULL
IFN-alpha/beta	NULL
genes	NULL
:	NULL
evidence	NULL
for	NULL
a	NULL
dual	NULL
function	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
complex	NULL
ISGF3	NULL
in	NULL
the	NULL
production	NULL
and	NULL
action	NULL
of	NULL
IFN-alpha/beta	NULL
.	NULL

Genes	NULL
Cells	NULL
1996	NULL
;	NULL
1:995-1005	NULL
.	NULL

Kimura	NULL
T	NULL
,	NULL
Kadokawa	NULL
Y	NULL
,	NULL
Harada	NULL
H	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Essential	NULL
and	NULL
non-redundant	NULL
roles	NULL
of	NULL
p48	NULL
(	NULL
ISGF3	NULL
gamma	NULL
)	NULL
and	NULL
IRF-1	NULL
in	NULL
both	NULL
type	NULL
I	NULL
and	NULL
type	NULL
II	NULL
interferon	NULL
re-sponses	NULL
,	NULL
as	NULL
revealed	NULL
by	NULL
gene	NULL
targeting	NULL
studies	NULL
.	NULL

Genes	NULL
Cells	NULL
.	NULL

1996	NULL
;	NULL
1:115-124	NULL
.	NULL

Means	NULL
RTJ	NULL
,	NULL
Krantz	NULL
SB	NULL
.	NULL

Inhibition	NULL
of	NULL
human	NULL
erythroid	NULL
colony-forming	NULL
units	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
requires	NULL
beta	NULL
interferon	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

1993	NULL
;	NULL
91:416-419	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

Matsuyama	NULL
T	NULL
,	NULL
Kimura	NULL
T	NULL
,	NULL
Kitagawa	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Targeted	NULL
disruption	NULL
of	NULL
IRF-1	NULL
or	NULL
IRF-2	NULL
results	NULL
in	NULL
abnormal	NULL
type	NULL
|	NULL
IFN	NULL
gene	NULL
induction	NULL
and	NULL
aberrant	NULL
lymphocyte	NULL
development	NULL
.	NULL

Cell	NULL
.	NULL

1993	NULL
;	NULL
75:83-97	NULL
.	NULL

Tanaka	NULL
N	NULL
,	NULL
Ishihara	NULL
M	NULL
,	NULL
Kitagawa	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cellular	NULL
commitment	NULL
to	NULL
oncogene-induced	NULL
transformation	NULL
or	NULL
apoptosis	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
transcription	NULL
factor	NULL
IRF-1	NULL
.	NULL

Cell	NULL
.	NULL

1994	NULL
;	NULL
77:829-839	NULL
.	NULL

Prost	NULL
S	NULL
,	NULL
Bellamy	NULL
CO	NULL
,	NULL
Cunningham	NULL
DS	NULL
,	NULL
Harrison	NULL
DJ	NULL
.	NULL

Altered	NULL
DNA	NULL
repair	NULL
and	NULL
dysregulation	NULL
of	NULL
p53	NULL
in	NULL
IRF-1	NULL
null	NULL
hepatocytes	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

1998	NULL
;	NULL
12	NULL
:	NULL
181-188	NULL
.	NULL

Pavlovic	NULL
J	NULL
,	NULL
Arzet	NULL
HA	NULL
,	NULL
Hefti	NULL
HP	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Enhanced	NULL
virus	NULL
resistance	NULL
of	NULL
transgenic	NULL
mice	NULL
expressing	NULL
the	NULL
human	NULL
MxA	NULL
protein	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1995	NULL
;	NULL
69:4506-4510	NULL
.	NULL

Pitossi	NULL
F	NULL
,	NULL
Blank	NULL
A	NULL
,	NULL
Schroder	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

A	NULL
functional	NULL
GTP-binding	NULL
motif	NULL
is	NULL
necessary	NULL
for	NULL
antiviral	NULL
activity	NULL
of	NULL
Mx	NULL
proteins	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1993	NULL
;	NULL
67:6726-6732	NULL
.	NULL

Li	NULL
Y	NULL
,	NULL
Youssoutfian	NULL
H.	NULL
MxA	NULL
overexpression	NULL
reveals	NULL
a	NULL
common	NULL
genetic	NULL
link	NULL
in	NULL
four	NULL
Fanconi	NULL
anemia	NULL
complementation	NULL
groups	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

1997	NULL
;	NULL
100	NULL
:	NULL
2873-2880	NULL
.	NULL

Thornton	NULL
AM	NULL
,	NULL
Ogryzko	NULL
VV	NULL
,	NULL
Dent	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

A	NULL
domi-	NULL
BLOOD	NULL
,	NULL
15	NULL
MAY	NULL
2001	NULL
Â«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
10	NULL
55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58.	NULL
nant	NULL
negative	NULL
mutant	NULL
of	NULL
an	NULL
IFN	NULL
regulatory	NULL
factor	NULL
family	NULL
protein	NULL
inhibits	NULL
both	NULL
type	NULL
|	NULL
and	NULL
type	NULL
II	NULL
IFN-stimulated	NULL
gene	NULL
expression	NULL
and	NULL
antiproliferative	NULL
activity	NULL
of	NULL
IFNs	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
157:5145-5154	NULL
.	NULL

Rathbun	NULL
RK	NULL
,	NULL
Christianson	NULL
TA	NULL
,	NULL
Faulkner	NULL
GR	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Interferon-gamma-induced	NULL
apoptotic	NULL
responses	NULL
of	NULL
Fanconi	NULL
anemia	NULL
group	NULL
C	NULL
hematopoietic	NULL
progenitor	NULL
cells	NULL
involve	NULL
caspase	NULL
8-dependent	NULL
activation	NULL
of	NULL
caspase	NULL
3	NULL
family	NULL
members	NULL
.	NULL

Blood	NULL
.	NULL

2000	NULL
;	NULL
4204-4211	NULL
.	NULL

Pang	NULL
Q	NULL
,	NULL
Keeble	NULL
W	NULL
,	NULL
Diaz	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Role	NULL
of	NULL
double-stranded	NULL
RNA-dependent	NULL
protein	NULL
kinase	NULL
in	NULL
mediating	NULL
hypersensitivity	NULL
of	NULL
Fanconi	NULL
anemia	NULL
complementation	NULL
group	NULL
C	NULL
cells	NULL
to	NULL
interferon	NULL
y	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
,	NULL
and	NULL
double-stranded	NULL
RNA	NULL
.	NULL

Blood	NULL
.	NULL

2001	NULL
;	NULL
97:1644-1652	NULL
.	NULL

Lavin	NULL
MF	NULL
,	NULL
Shiloh	NULL
Y	NULL
.	NULL

The	NULL
genetic	NULL
defect	NULL
in	NULL
ataxia-telangiectasia	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
.	NULL

1997	NULL
;	NULL
15:177-202	NULL
.	NULL

Xu	NULL
Y	NULL
,	NULL
Brugarolas	NULL
J	NULL
,	NULL
Jacks	NULL
T	NULL
,	NULL
Baltimore	NULL
D.	NULL
Involvement	NULL
of	NULL
p53	NULL
and	NULL
p21	NULL
in	NULL
cellular	NULL
defects	NULL
and	NULL
tu-morigenesis	NULL
in	NULL
Atm-/-	NULL
mice	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1998	NULL
;	NULL
18:4385-4391	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Â®	NULL
2001	NULL
97	NULL
:	NULL
3017-3024	NULL
doi:10.1182/blood.V97.10.3017	NULL
Functional	NULL
correction	NULL
of	NULL
FA-C	NULL
cells	NULL
with	NULL
FANCC	NULL
suppresses	NULL
the	NULL
expression	NULL
of	NULL
interferon	NULL
y-inducible	NULL
genes	NULL
A	NULL
TY	NULL
O	NULL
0C	NULL
,	NULL
f	NULL
Â£le	NULL
CA	NULL
N	NULL
,	NULL
a	NULL
'	NULL
*	NULL
f	NULL
)	NULL
..	NULL

I	NULL
f	NULL
2	NULL
``	NULL
O10	NULL
(	NULL
@	NULL
0	NULL
Sara	NULL
R.	NULL
Fagerlie	NULL
,	NULL
Jane	NULL
Diaz	NULL
,	NULL
Tracy	NULL
A.	NULL
Christianson	NULL
,	NULL
Kelli	NULL
McCartan	NULL
,	NULL
Winifred	NULL
Keeble	NULL
,	NULL
Gregory	NULL
R.	NULL
Faulkner	NULL
and	NULL
Grover	NULL
C.	NULL
Bagby	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/97/10/3017.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Hematopoiesis	NULL
and	NULL
Stem	NULL
Cells	NULL
(	NULL
3573	NULL
articles	NULL
)	NULL
Signal	NULL
Transduction	NULL
(	NULL
1930	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

